chrysene - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	chrysene	go back to main search page
Accession:	CHEBI:51687	browse the term
Definition:	An ortho-fused polycyclic arene found commonly in the coal tar.
Synonyms:	related_synonym:	1,2,5,6-dibenzonaphthalene; 1,2-Benzophenanthrene; Benz[a]phenanthrene; Chrysen; Formula=C18H12; InChI=1S/C18H12/c1-3-7-15-13(5-1)9-11-18-16-8-4-2-6-14(16)10-12-17(15)18/h1-12H; InChIKey=WDECIBYCCFPHNR-UHFFFAOYSA-N; SMILES=c1ccc2c(c1)ccc1c3ccccc3ccc21; benzo[a]phenanthrene
	alt_id:	CHEBI:33087; CHEBI:34639
	xref:	Beilstein:1909297; CAS:218-01-9; Gmelin:262600; KEGG:C14222
	xref_mesh:	MESH:C031180
	xref:	MetaCyc:CPD-13772; PMID:24128549; PMID:24382467; PMID:24519633; Wikipedia:Chrysene

show annotations for term's descendants Sort by:
Rat (870) Mouse (942) Human (883) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (0) Green Monkey (0) Naked Mole-rat (0) All
Genes (870)

chrysene

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aladin WD repeat nucleoporin

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of AAAS mRNA

NCBI chr 7:133,464,315...133,483,961
Ensembl chr 7:133,464,315...133,483,961

G

ATP binding cassette subfamily B member 1A

increases expression

chrysene results in increased expression of ABCB1 mRNA

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily C member 5

decreases expression
multiple interactions

chrysene results in decreased expression of ABCC5 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ABCC5 mRNA

PMID:26377693 PMID:27858113

NCBI chr11:80,473,809...80,567,257
Ensembl chr11:80,473,872...80,567,253

G

ABI family member 3 binding protein

increases expression
multiple interactions

chrysene results in increased expression of ABI3BP mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ABI3BP mRNA

PMID:26377693 PMID:27858113

NCBI chr11:43,912,187...44,128,888
Ensembl chr11:43,913,043...44,128,929

G

actin-binding LIM protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ABLIM1 mRNA

NCBI chr 1:256,083,747...256,372,075
Ensembl chr 1:256,084,297...256,371,969

G

abraxas 2, BRISC complex subunit

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ABRAXAS2 mRNA

NCBI chr 1:187,647,078...187,672,660
Ensembl chr 1:187,647,067...187,672,655

G

apoptotic chromatin condensation inducer 1

decreases expression
multiple interactions

chrysene results in decreased expression of ACIN1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ACIN1 mRNA

PMID:26377693 PMID:27858113

NCBI chr15:28,102,112...28,147,001
Ensembl chr15:28,102,112...28,147,001

G

aconitate decarboxylase 1

decreases expression

chrysene results in decreased expression of ACOD1 mRNA

NCBI chr15:79,871,819...79,881,101
Ensembl chr15:79,871,827...79,880,529

G

acyl-CoA thioesterase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ACOT1 mRNA

NCBI chr 6:103,636,173...103,644,167
Ensembl chr 6:103,636,041...103,644,163

G

acyl-CoA oxidase-like

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ACOXL mRNA

NCBI chr 3:115,061,069...115,367,032
Ensembl chr 3:115,061,060...115,364,686

G

actin, alpha 1, skeletal muscle

increases expression

chrysene results in increased expression of ACTA1 mRNA

NCBI chr19:51,883,709...51,886,735
Ensembl chr19:51,883,715...51,886,742

G

actinin alpha 3

increases expression

chrysene results in increased expression of ACTN3 mRNA

NCBI chr 1:202,159,081...202,175,012
Ensembl chr 1:202,159,082...202,175,012

G

adenosine deaminase

increases expression

chrysene results in increased expression of ADA mRNA

NCBI chr 3:152,398,745...152,422,854
Ensembl chr 3:152,398,747...152,447,088

G

ADAM metallopeptidase domain 33

increases expression

chrysene results in increased expression of ADAM33 mRNA

NCBI chr 3:118,262,395...118,283,456
Ensembl chr 3:118,271,029...118,283,461

G

ADAM-like, decysin 1

increases expression

chrysene results in increased expression of ADAMDEC1 mRNA

NCBI chr15:42,900,629...42,921,684
Ensembl chr15:42,900,636...42,921,712

G

ADAM metallopeptidase with thrombospondin type 1 motif, 14

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ADAMTS14 mRNA

NCBI chr20:29,143,029...29,219,846
Ensembl chr20:29,144,354...29,219,866

G

adducin 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ADD3 mRNA

NCBI chr 1:252,147,341...252,255,126
Ensembl chr 1:252,147,386...252,255,124

G

adhesion G protein-coupled receptor D1

increases expression

chrysene results in increased expression of ADGRD1 mRNA

NCBI chr12:27,488,908...27,603,714
Ensembl chr12:27,488,908...27,603,696

G

adhesion G protein-coupled receptor L4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ADGRL4 mRNA

NCBI chr 2:240,354,909...240,457,231
Ensembl chr 2:240,354,941...240,457,225

G

adrenomedullin

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ADM mRNA

NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654

G

apoptosis enhancing nuclease

increases expression
multiple interactions

chrysene results in increased expression of AEN mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of AEN mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:132,815,094...132,824,522
Ensembl chr 1:132,815,142...132,824,523

G

AGBL carboxypeptidase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AGBL2 mRNA

NCBI chr 3:76,764,893...76,800,071
Ensembl chr 3:76,764,238...76,800,214

G

argonaute RISC catalytic component 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AGO2 mRNA

NCBI chr 7:105,018,202...105,105,118
Ensembl chr 7:105,029,120...105,104,974

G

adenosylhomocysteinase-like 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AHCYL2 mRNA

NCBI chr 4:58,381,290...58,531,061
Ensembl chr 4:58,381,218...58,531,060

G

AHNAK nucleoprotein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AHNAK mRNA

NCBI chr 1:205,882,225...205,970,934
Ensembl chr 1:205,882,273...205,970,926

G

aryl hydrocarbon receptor

multiple interactions
affects response to substance
increases activity
affects binding

chrysene binds to and results in increased activity of AHR protein
AHR affects the susceptibility to chrysene
[benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [indeno(1,2,3-cd)pyrene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene] promotes the reaction [pyrene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with pyrene] promotes the reaction [fluoranthene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [chrysene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [benzo(k)fluoranthene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with Benzo(a)pyrene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [benzo(j)fluoranthene results in increased activity of AHR protein]; [benz(a)anthracene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [Benzo(a)pyrene results in increased activity of AHR protein]; [Benzo(a)pyrene co-treated with benzo(j)fluoranthene co-treated with benzo(k)fluoranthene co-treated with chrysene co-treated with indeno(1,2,3-cd)pyrene co-treated with fluoranthene co-treated with pyrene] promotes the reaction [benz(a)anthracene results in increased activity of AHR protein]; [chrysene binds to and results in increased activity of AHR protein] which results in increased expression of CYP1A1 mRNA; alpha-naphthoflavone inhibits the reaction [[chrysene binds to and results in increased activity of AHR protein] which results in increased expression of CYP1A1 mRNA]; chrysene binds to and results in increased activity of AHR protein; chrysene promotes the reaction [AHR protein results in increased expression of CYP1A1 mRNA]
chrysene binds to AHR protein
chrysene analog results in increased activity of AHR protein; chrysene results in increased activity of AHR protein

PMID:3024361 PMID:8571374 PMID:11525907 PMID:12371477 PMID:12799773 More...

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

aryl-hydrocarbon receptor repressor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of AHRR mRNA

NCBI chr 1:28,993,634...29,088,673
Ensembl chr 1:28,993,634...29,088,673

G

allograft inflammatory factor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AIF1 mRNA

NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668

G

A-kinase anchoring protein 12

increases expression

chrysene results in increased expression of AKAP12 mRNA

NCBI chr 1:40,730,123...40,819,863
Ensembl chr 1:40,730,123...40,819,886

G

A-kinase anchoring protein 7

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AKAP7 mRNA

NCBI chr 1:20,087,190...20,217,799
Ensembl chr 1:20,087,373...20,217,797

G

aldo-keto reductase family 1, member C1

increases expression

chrysene results in increased expression of AKR1C1 mRNA

NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326

G

ALG14, UDP-N-acetylglucosaminyltransferase subunit

decreases expression

chrysene results in decreased expression of ALG14 mRNA

NCBI chr 2:209,368,285...209,445,425
Ensembl chr 2:209,368,312...209,445,431

G

alkB homolog 7

decreases expression

chrysene results in decreased expression of ALKBH7 mRNA

NCBI chr 9:1,838,886...1,841,044
Ensembl chr 9:1,838,811...1,841,044

G

arachidonate lipoxygenase 3

increases expression

chrysene results in increased expression of ALOXE3 mRNA

NCBI chr10:53,830,219...53,854,328
Ensembl chr10:53,831,264...53,854,328

G

ALS2 C-terminal like

increases expression

chrysene results in increased expression of ALS2CL mRNA

NCBI chr 8:110,863,753...110,884,434
Ensembl chr 8:110,864,975...110,884,419

G

angiopoietin-like 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ANGPTL4 mRNA

NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519

G

ankyrin 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ANK3 mRNA

NCBI chr20:18,602,267...19,225,831
Ensembl chr20:18,602,786...19,086,300

G

ankyrin repeat domain 12

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ANKRD12 mRNA

NCBI chr 9:105,583,273...105,687,957
Ensembl chr 9:105,584,065...105,687,911

G

ankyrin repeat domain containing 26

decreases expression

chrysene results in decreased expression of ANKRD26 mRNA

NCBI chr 4:151,670,604...151,740,032
Ensembl chr 4:151,672,037...151,739,968

G

alanyl aminopeptidase, membrane

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ANPEP mRNA

NCBI chr 1:133,767,332...133,810,137
Ensembl chr 1:133,767,332...133,785,789

G

adaptor related protein complex 1 subunit sigma 1

increases expression

chrysene results in increased expression of AP1S1 mRNA

NCBI chr12:19,625,267...19,635,792
Ensembl chr12:19,625,332...19,756,713

G

apolipoprotein L9a

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of APOL9A mRNA

NCBI chr 7:109,140,871...109,149,799
Ensembl chr 7:109,140,871...109,147,649

G

androgen receptor

multiple interactions
increases activity
decreases activity

chrysene binds to and results in decreased activity of AR protein; chrysene inhibits the reaction [Metribolone results in increased activity of AR protein]
chrysene results in increased activity of AR protein
chrysene results in decreased activity of AR protein

PMID:10771140 PMID:12799773 PMID:18324785

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

amphiregulin

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of AREG mRNA

NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535

G

arginine and glutamate rich 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ARGLU1 mRNA

NCBI chr16:80,753,300...80,777,350
Ensembl chr16:80,753,315...80,777,349

G

Rho GTPase activating protein 23

decreases expression

chrysene results in decreased expression of ARHGAP23 mRNA

NCBI chr10:82,437,578...82,496,846
Ensembl chr10:82,394,648...82,496,504

G

Rho guanine nucleotide exchange factor 38

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ARHGEF38 mRNA

NCBI chr 2:221,610,212...221,739,841
Ensembl chr 2:221,613,070...221,740,079

G

Rho guanine nucleotide exchange factor 40

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ARHGEF40 mRNA

NCBI chr15:24,672,645...24,696,510
Ensembl chr15:24,672,763...24,696,510

G

ADP ribosylation factor like GTPase 3

decreases expression

chrysene results in decreased expression of ARL3 mRNA

NCBI chr 1:245,400,659...245,446,673
Ensembl chr 1:245,400,550...245,446,820

G

armadillo repeat containing 6

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ARMC6 mRNA

NCBI chr16:19,191,106...19,201,528
Ensembl chr16:19,191,093...19,206,047

G

arrestin domain containing 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ARRDC4 mRNA

NCBI chr 1:122,369,355...122,383,351
Ensembl chr 1:122,369,360...122,383,290

G

asialoglycoprotein receptor 2

decreases expression
multiple interactions

chrysene results in decreased expression of ASGR2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ASGR2 mRNA

PMID:26377693 PMID:27858113

NCBI chr10:54,821,407...54,834,624
Ensembl chr10:54,821,438...54,834,617

G

aspartate-beta-hydroxylase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ASPH mRNA

NCBI chr 5:22,601,581...22,814,107
Ensembl chr 5:22,603,486...22,813,876

G

aspartic peptidase, retroviral-like 1

increases expression

chrysene results in increased expression of ASPRV1 mRNA

NCBI chr 4:119,077,415...119,078,887
Ensembl chr 4:119,077,356...119,078,379

G

activating transcription factor 4

increases expression

chrysene results in increased expression of ATF4 mRNA

NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446

G

autophagy related 4C, cysteine peptidase

increases expression

chrysene results in increased expression of ATG4C mRNA

NCBI chr 5:113,867,218...113,935,534
Ensembl chr 5:113,867,092...113,934,830

G

ATPase 13A3

decreases expression
multiple interactions

chrysene results in decreased expression of ATP13A3 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ATP13A3 mRNA

PMID:26377693 PMID:27858113

NCBI chr11:70,364,998...70,442,005
Ensembl chr11:70,365,322...70,441,235

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ATP2A2 mRNA

NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101

G

ATP synthase membrane subunit G

decreases expression

chrysene results in decreased expression of ATP5MG mRNA

NCBI chr 8:45,225,680...45,233,630
Ensembl chr 8:45,225,686...45,233,559

G

ATPase H+ transporting V0 subunit a1

increases expression

chrysene results in increased expression of ATP6V0A1 mRNA

NCBI chr10:85,935,802...85,989,901
Ensembl chr10:85,935,854...85,989,895

G

ATPase H+ transporting V0 subunit a4

increases expression

chrysene results in increased expression of ATP6V0A4 mRNA

NCBI chr 4:66,760,163...66,842,126
Ensembl chr 4:66,760,159...66,842,110

G

ATPase H+ transporting V0 subunit e1

decreases expression

chrysene results in decreased expression of ATP6V0E mRNA

NCBI chr10:16,479,656...16,502,732
Ensembl chr10:16,479,567...16,524,434

G

ataxin 3

increases expression

chrysene results in increased expression of ATXN3 mRNA

NCBI chr 6:121,072,228...121,107,902
Ensembl chr 6:121,074,448...121,107,902

G

beta-1,4-galactosyltransferase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of B4GALT1 mRNA

NCBI chr 5:55,935,614...55,982,461
Ensembl chr 5:55,935,615...55,982,461

G

basic leucine zipper ATF-like transcription factor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of BATF mRNA

NCBI chr 6:105,353,715...105,376,051
Ensembl chr 6:105,353,715...105,376,051

G

BCL2 associated X, apoptosis regulator

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BAX mRNA

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

butyrylcholinesterase

increases expression

chrysene results in increased expression of BCHE mRNA

NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148

G

branched chain keto acid dehydrogenase E1 subunit beta

decreases expression

chrysene results in decreased expression of BCKDHB mRNA

NCBI chr 8:84,845,264...85,027,812
Ensembl chr 8:84,845,264...85,027,812

G

BCL11 transcription factor A

increases expression

chrysene results in increased expression of BCL11A mRNA

NCBI chr14:98,029,018...98,124,181
Ensembl chr14:98,030,461...98,124,180

G

BCL3, transcription coactivator

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of BCL3 mRNA

NCBI chr 1:79,471,368...79,485,908
Ensembl chr 1:79,471,369...79,485,607

G

BCL6B, transcription repressor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BCL6B mRNA

NCBI chr10:54,940,908...54,947,022
Ensembl chr10:54,940,909...54,945,974

G

BAF chromatin remodeling complex subunit BCL7B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of BCL7B mRNA

NCBI chr12:21,496,860...21,510,079
Ensembl chr12:21,496,856...21,510,202

G

BCL2-associated transcription factor 1

increases expression

chrysene results in increased expression of BCLAF1 mRNA

NCBI chr 1:15,088,436...15,117,666
Ensembl chr 1:15,070,894...15,148,832

G

basic helix-loop-helix family, member e40

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BHLHE40 mRNA

NCBI chr 4:141,618,453...141,624,154
Ensembl chr 4:141,618,476...141,624,774

G

baculoviral IAP repeat-containing 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BIRC5 mRNA

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

biogenesis of lysosomal organelles complex-1, subunit 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BLOC1S2 mRNA

NCBI chr 1:243,024,611...243,031,749
Ensembl chr 1:243,024,614...243,031,653

G

basic helix-loop-helix ARNT like 1

decreases expression
multiple interactions

chrysene results in decreased expression of BMAL1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of BMAL1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231

G

bone morphogenetic protein receptor type 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of BMPR2 mRNA

NCBI chr 9:61,192,718...61,307,280
Ensembl chr 9:61,190,566...61,301,809

G

bromodomain containing 7

increases expression

chrysene results in increased expression of BRD7 mRNA

NCBI chr19:18,708,792...18,737,497
Ensembl chr19:18,709,022...18,737,494

G

BSCL2 lipid droplet biogenesis associated, seipin

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BSCL2 mRNA

NCBI chr 1:205,731,828...205,743,430
Ensembl chr 1:205,733,872...205,743,421

G

B and T lymphocyte associated

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of BTLA mRNA

NCBI chr11:55,563,683...55,588,187
Ensembl chr11:55,564,899...55,587,181

G

C2 domain containing 3 centriole elongation regulator

decreases expression
multiple interactions

chrysene results in decreased expression of C2CD3 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of C2CD3 mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:154,715,151...154,812,955
Ensembl chr 1:154,715,310...154,812,520

G

complement C5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HC mRNA

NCBI chr 3:18,270,696...18,361,994
Ensembl chr 3:18,270,696...18,361,994

G

complement C5a receptor 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of C5AR2 mRNA

NCBI chr 1:76,930,381...76,945,432
Ensembl chr 1:76,930,383...76,959,517

G

complement C7

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of C7 mRNA

NCBI chr 2:54,088,116...54,165,102
Ensembl chr 2:54,088,116...54,158,535

G

calcium binding protein 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CABP5 mRNA

NCBI chr 1:74,350,811...74,363,830
Ensembl chr 1:74,350,811...74,363,830

G

calcium voltage-gated channel auxiliary subunit gamma 1

increases expression

chrysene results in increased expression of CACNG1 mRNA

NCBI chr10:92,652,924...92,665,612
Ensembl chr10:92,652,614...92,665,783

G

calmodulin-like 5

increases expression

chrysene results in increased expression of CALM4 mRNA

NCBI chr17:66,394,433...66,395,352

G

calpain 3

increases expression

chrysene results in increased expression of CAPN3 mRNA

NCBI chr 3:107,407,518...107,457,858
Ensembl chr 3:107,407,850...107,457,858

G

capping actin protein of muscle Z-line subunit alpha 2

decreases expression

chrysene results in decreased expression of CAPZA2 mRNA

NCBI chr 4:45,978,142...46,014,032
Ensembl chr 4:45,977,807...46,013,864

G

carbonic anhydrase 14

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CAR14 mRNA

NCBI chr 2:183,442,263...183,449,231
Ensembl chr 2:183,441,667...183,449,693

G

capping protein regulator and myosin 1 linker 1

decreases expression

chrysene results in decreased expression of CARMIL1 mRNA

NCBI chr17:40,807,921...41,088,326
Ensembl chr17:40,808,389...41,088,326

G

caspase 3

increases activity

chrysene results in increased activity of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

castor zinc finger 1

increases expression

chrysene results in increased expression of CASZ1 mRNA

NCBI chr 5:159,243,965...159,393,935
Ensembl chr 5:159,243,995...159,393,400

G

catalase

decreases activity

chrysene results in decreased activity of CAT protein

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

caveolin 1

decreases expression
multiple interactions

chrysene results in decreased expression of CAV1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CAV1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705

G

caveolae associated protein 1

increases expression

chrysene results in increased expression of CAVIN1 mRNA

NCBI chr10:85,884,100...85,896,136
Ensembl chr10:85,889,036...85,896,120

G

CBFA2/RUNX1 partner transcriptional co-repressor 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CBFA2T3 mRNA

NCBI chr19:50,679,897...50,750,028
Ensembl chr19:50,680,729...50,749,610

G

collagen and calcium binding EGF domains 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCBE1 mRNA

NCBI chr18:59,579,851...59,823,977
Ensembl chr18:59,580,768...59,824,400

G

coiled-coil domain containing 184

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCDC184 mRNA

NCBI chr 7:129,297,635...129,301,961
Ensembl chr 7:129,298,212...129,304,494

G

coiled-coil domain containing 82

increases expression

chrysene results in increased expression of CCDC82 mRNA

NCBI chr 8:10,227,727...10,265,963
Ensembl chr 8:10,228,430...10,265,963

G

C-C motif chemokine ligand 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CCL4 mRNA

NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231

G

C-C motif chemokine ligand 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CCL5 mRNA

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

C-C motif chemokine ligand 9

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCL6 mRNA

NCBI chr10:68,366,486...68,371,408
Ensembl chr10:68,366,487...68,371,369

G

CCM2 like scaffold protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCM2L mRNA

NCBI chr 3:141,533,470...141,549,136
Ensembl chr 3:141,533,511...141,549,140

G

cyclin D1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCND1 mRNA

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin D2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCND2 mRNA

NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495

G

cyclin D1 binding protein 1

decreases expression

chrysene results in decreased expression of CCNDBP1 mRNA

NCBI chr 3:107,962,402...107,974,234
Ensembl chr 3:107,962,261...107,974,233

G

cyclin G1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCNG1 mRNA

NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641

G

cyclin J-like

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CCNJL mRNA

NCBI chr10:27,995,682...28,053,428
Ensembl chr10:27,995,679...28,053,426

G

cyclin L1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CCNL1 mRNA

NCBI chr 2:150,184,865...150,199,524
Ensembl chr 2:150,184,798...150,197,368

G

cyclin L2

increases expression

chrysene results in increased expression of CCNL2 mRNA

NCBI chr 5:166,416,940...166,428,997
Ensembl chr 5:166,417,508...166,436,882

G

C-C motif chemokine receptor 7

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CCR7 mRNA

NCBI chr10:84,098,193...84,108,309
Ensembl chr10:84,097,381...84,108,309

G

CD151 molecule (Raph blood group)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD151 mRNA

NCBI chr 1:196,564,744...196,568,753
Ensembl chr 1:196,565,181...196,568,753

G

Cd200 molecule

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD200 mRNA

NCBI chr11:55,410,166...55,437,527
Ensembl chr11:55,410,196...55,501,648

G

CD248 molecule

increases expression

chrysene results in increased expression of CD248 mRNA

NCBI chr 1:202,373,676...202,376,240
Ensembl chr 1:202,373,676...202,376,240

G

CD34 molecule

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD34 mRNA

NCBI chr13:106,480,313...106,500,844
Ensembl chr13:106,480,043...106,499,832

G

CD37 molecule

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD37 mRNA

NCBI chr 1:95,719,171...95,724,662
Ensembl chr 1:95,719,190...95,724,648

G

Cd47 molecule

decreases expression

chrysene results in decreased expression of CD47 mRNA

NCBI chr11:50,906,052...50,970,000
Ensembl chr11:50,906,177...50,969,425

G

Cd48 molecule

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD48 mRNA

NCBI chr13:84,184,884...84,209,144
Ensembl chr13:84,185,532...84,209,142

G

CD55 molecule (Cromer blood group)

increases expression

chrysene results in increased expression of CD55 mRNA

NCBI chr13:41,857,242...41,885,966
Ensembl chr13:41,857,395...41,885,831

G

Cd69 molecule

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD69 mRNA

NCBI chr 4:162,725,446...162,733,364
Ensembl chr 4:162,725,446...162,733,542

G

CD79b molecule

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CD79B mRNA

NCBI chr10:91,239,354...91,242,500
Ensembl chr10:91,239,356...91,242,625

G

CD99 molecule (Xg blood group)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CD99 mRNA

NCBI chr20:54,418,239...54,422,882

G

cell division cycle 14B

increases expression

chrysene results in increased expression of CDC14B mRNA

NCBI chr17:844,686...934,787
Ensembl chr17:844,685...933,235

G

cell division cycle 42

decreases expression

chrysene results in decreased expression of CDC42 mRNA

NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111

G

cadherin 13

increases expression

chrysene results in increased expression of CDH13 mRNA

NCBI chr19:46,349,562...47,387,462
Ensembl chr19:46,349,430...47,387,459

G

cadherin 16

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CDH16 mRNA

NCBI chr19:360,824...371,008
Ensembl chr19:360,824...371,007

G

cadherin 3

increases expression

chrysene results in increased expression of CDH3 mRNA

NCBI chr19:34,393,596...34,444,084
Ensembl chr19:34,393,727...34,444,084

G

cadherin-related family member 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CDHR4 mRNA

NCBI chr 8:108,682,594...108,690,358
Ensembl chr 8:108,682,613...108,690,367

G

cyclin-dependent kinase 14

decreases expression

chrysene results in decreased expression of CDK14 mRNA

NCBI chr 4:28,666,416...29,258,865
Ensembl chr 4:28,666,843...29,258,861

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CDKN1A mRNA

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

CCAAT/enhancer binding protein delta

decreases expression

chrysene results in decreased expression of CEBPD mRNA

NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829

G

CUGBP, Elav-like family member 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CELF5 mRNA

NCBI chr 7:8,225,787...8,250,322
Ensembl chr 7:8,225,825...8,250,322

G

cadherin, EGF LAG seven-pass G-type receptor 2

increases expression

chrysene results in increased expression of CELSR2 mRNA

NCBI chr 2:196,029,206...196,053,848
Ensembl chr 2:196,029,434...196,053,845

G

centrosomal protein 162

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CEP162 mRNA

NCBI chr 8:88,149,726...88,208,249
Ensembl chr 8:88,149,726...88,206,830

G

centrosomal protein 41

decreases expression

chrysene results in decreased expression of CEP41 mRNA

NCBI chr 4:59,271,218...59,312,343
Ensembl chr 4:59,271,218...59,310,668

G

centrosomal protein 63

increases expression

chrysene results in increased expression of CEP63 mRNA

NCBI chr 8:103,162,639...103,214,177
Ensembl chr 8:103,162,700...103,214,177

G

carboxylesterase 2C

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CES2C mRNA

NCBI chr 1:260,391,190...260,398,757
Ensembl chr 1:260,388,902...260,398,790

G

carboxylesterase 2E

multiple interactions
increases expression

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CES2E mRNA
chrysene results in increased expression of CES2E mRNA

PMID:26377693 PMID:27858113

NCBI chr19:157,447...172,822
Ensembl chr19:157,407...172,856

G

complement factor B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CFB mRNA

NCBI chr20:3,970,643...3,976,510
Ensembl chr20:3,951,474...3,976,505

G

chromodomain helicase DNA binding protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CHD2 mRNA

NCBI chr 1:127,188,146...127,317,041
Ensembl chr 1:127,190,059...127,300,502

G

chitinase, acidic

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CHIA mRNA

NCBI chr 2:193,614,374...193,656,532
Ensembl chr 2:193,614,114...193,656,533

G

choline kinase alpha

decreases expression

chrysene results in decreased expression of CHKA mRNA

NCBI chr 1:201,076,804...201,125,517
Ensembl chr 1:201,076,860...201,125,516

G

carbohydrate sulfotransferase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CHST1 mRNA

NCBI chr 3:78,552,059...78,574,740
Ensembl chr 3:78,548,525...78,574,883

G

cold inducible RNA binding protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CIRBP mRNA

NCBI chr 7:9,533,857...9,538,899
Ensembl chr 7:9,424,178...9,538,818

G

cytokine inducible SH2-containing protein

decreases expression

chrysene results in decreased expression of CISH mRNA

NCBI chr 8:107,972,306...107,977,254
Ensembl chr 8:107,972,306...107,977,250

G

Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CITED2 mRNA

NCBI chr 1:12,312,426...12,314,869
Ensembl chr 1:12,312,160...12,314,897

G

cytoskeleton associated protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CKAP2 mRNA

NCBI chr16:69,839,668...69,864,852
Ensembl chr16:69,839,630...69,864,913

G

CLK4-associating serine/arginine rich protein

increases expression

chrysene results in increased expression of SFRS16 mRNA

NCBI chr 1:79,232,260...79,256,462
Ensembl chr 1:79,232,261...79,256,354

G

C-type lectin domain family 1, member A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CLEC1A mRNA

NCBI chr 4:162,875,360...162,902,571
Ensembl chr 4:162,877,346...162,901,247

G

C-type lectin domain family 4, member A1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CLEC4A1 mRNA

NCBI chr 4:156,173,894...156,186,009
Ensembl chr 4:156,173,894...156,186,008

G

C-type lectin domain family 4, member F

decreases expression

chrysene results in decreased expression of CLEC4F mRNA

NCBI chr 4:116,129,023...116,138,744
Ensembl chr 4:116,129,023...116,138,775

G

C-type lectin domain family 4, member G

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CLEC4G mRNA

NCBI chr12:1,780,370...1,785,027
Ensembl chr12:1,780,371...1,784,985

G

CDC-like kinase 4

increases expression

chrysene results in increased expression of CLK4 mRNA

NCBI chr10:35,523,382...35,541,387
Ensembl chr10:35,524,755...35,541,352

G

calsyntenin 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CLSTN2 mRNA

NCBI chr 8:98,020,406...98,637,232
Ensembl chr 8:98,021,666...98,637,731

G

cytidine/uridine monophosphate kinase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CMPK2 mRNA

NCBI chr 6:43,073,706...43,085,183
Ensembl chr 6:43,073,796...43,085,183

G

cordon-bleu WH2 repeat protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of COBL mRNA

NCBI chr14:86,828,137...87,060,682
Ensembl chr14:86,828,139...87,060,800

G

collagen type XVII alpha 1 chain

increases expression

chrysene results in increased expression of COL17A1 mRNA

NCBI chr 1:246,530,589...246,577,559
Ensembl chr 1:246,531,367...246,577,632

G

collagen type I alpha 1 chain

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of COL1A1 mRNA

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type I alpha 2 chain

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of COL1A2 mRNA

NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867

G

collagen type XX alpha 1 chain

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of COL20A1 mRNA

NCBI chr 3:168,102,475...168,134,759
Ensembl chr 3:168,084,560...168,135,309

G

collagen type III alpha 1 chain

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of COL3A1 mRNA

NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547

G

collagen type IV alpha 4 chain

decreases expression
multiple interactions

chrysene results in decreased expression of COL4A4 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of COL4A4 mRNA

PMID:26377693 PMID:27858113

NCBI chr 9:83,833,173...83,875,436
Ensembl chr 9:83,755,515...83,875,876

G

collagen type IV alpha 6 chain

increases expression

chrysene results in increased expression of COL4A6 mRNA

NCBI chr X:104,766,463...105,117,499
Ensembl chr X:104,766,957...105,117,500

G

collagen type V alpha 3 chain

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of COL5A3 mRNA

NCBI chr 8:19,304,564...19,349,809
Ensembl chr 8:19,304,571...19,349,853

G

COMM domain containing 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of COMMD3 mRNA

NCBI chr17:81,327,444...81,331,191
Ensembl chr17:81,327,405...81,331,177

G

COPI coat complex subunit epsilon

decreases expression

chrysene results in decreased expression of COPE mRNA

NCBI chr16:19,114,871...19,125,076
Ensembl chr16:19,114,871...19,128,907

G

coordinator of PRMT5 and differentiation stimulator

decreases expression

chrysene results in decreased expression of COPRS mRNA

NCBI chr16:75,721,264...75,726,375
Ensembl chr16:75,720,061...75,726,375

G

coenzyme Q10B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of COQ10B mRNA

NCBI chr 9:56,553,751...56,573,671
Ensembl chr 9:56,553,758...56,573,663

G

coenzyme Q8A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of COQ8A mRNA

NCBI chr13:91,904,731...91,933,588
Ensembl chr13:91,904,739...91,931,431

G

coronin 2A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CORO2A mRNA

NCBI chr 5:60,825,630...60,881,917
Ensembl chr 5:60,828,247...60,859,035

G

complexin 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CPLX2 mRNA

NCBI chr17:10,219,577...10,292,835
Ensembl chr17:10,222,347...10,293,855

G

copine 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CPNE4 mRNA

NCBI chr 8:105,177,376...105,653,075
Ensembl chr 8:105,177,376...105,653,068

G

copine 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CPNE5 mRNA

NCBI chr20:7,206,742...7,289,309
Ensembl chr20:7,206,742...7,288,883

G

carnitine palmitoyltransferase 1c

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CPT1C mRNA

NCBI chr 1:95,442,814...95,457,347
Ensembl chr 1:95,442,817...95,457,342

G

carboxypeptidase X (M14 family), member 2

increases expression

chrysene results in increased expression of CPXM2 mRNA

NCBI chr 1:186,836,797...186,947,222
Ensembl chr 1:186,836,797...186,947,220

G

complement C3d receptor 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CR2 mRNA

NCBI chr13:106,678,579...106,716,595
Ensembl chr13:106,685,413...106,716,235

G

cysteine-rich C-terminal 1

increases expression

chrysene results in increased expression of CRCT1 mRNA

NCBI chr 2:178,633,789...178,635,274
Ensembl chr 2:178,634,092...178,634,394

G

cysteine-rich secretory protein LCCL domain containing 2

increases expression

chrysene results in increased expression of CRISPLD2 mRNA

NCBI chr19:48,053,153...48,111,485
Ensembl chr19:48,053,287...48,110,465

G

CRK proto-oncogene, adaptor protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CRK mRNA

NCBI chr10:60,530,469...60,556,703
Ensembl chr10:60,530,464...60,553,406

G

casein kinase 1, gamma 2

increases expression

chrysene results in increased expression of CSNK1G2 mRNA

NCBI chr 7:9,076,739...9,095,082
Ensembl chr 7:9,076,740...9,095,052

G

cystatin 8

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CST8 mRNA

NCBI chr 3:136,244,586...136,255,412
Ensembl chr 3:136,244,636...136,251,273

G

C-X-C motif chemokine ligand 13

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CXCL13 mRNA

NCBI chr14:13,608,894...13,613,965
Ensembl chr14:13,608,902...13,613,933

G

C-X-C motif chemokine receptor 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CXCR5 mRNA

NCBI chr 8:44,842,098...44,858,425
Ensembl chr 8:44,843,413...44,857,893

G

C-X-C motif chemokine receptor 6

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CXCR6 mRNA

NCBI chr 8:123,434,417...123,439,568
Ensembl chr 8:123,416,325...123,439,526

G

CYLD lysine 63 deubiquitinase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CYLD mRNA

NCBI chr19:18,310,632...18,373,696
Ensembl chr19:18,314,019...18,373,658

G

cytochrome P450, family 17, subfamily a, polypeptide 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of CYP17A1 mRNA

NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
increases expression
increases activity
decreases expression

[chrysene binds to and results in increased activity of AHR protein] which results in increased expression of CYP1A1 mRNA; [CYP1A1 protein co-treated with Trichloroepoxypropane] results in increased metabolism of chrysene; alpha-naphthoflavone inhibits the reaction [[chrysene binds to and results in increased activity of AHR protein] which results in increased expression of CYP1A1 mRNA]; chrysene promotes the reaction [AHR protein results in increased expression of CYP1A1 mRNA]; EPHX1 protein promotes the reaction [CYP1A1 protein results in increased metabolism of chrysene]
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CYP1A1 mRNA; [CYP1A1 protein co-treated with Trichloroepoxypropane] results in increased metabolism of chrysene; [fluoranthene co-treated with pyrene co-treated with benz(a)anthracene co-treated with chrysene co-treated with benzo(b)fluoranthene co-treated with benzo(k)fluoranthene co-treated with Benzo(a)pyrene] results in increased expression of CYP1A1 mRNA; EPHX1 protein promotes the reaction [CYP1A1 protein results in increased metabolism of chrysene]
[chrysene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene] promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]; [chrysene co-treated with benz(a)anthracene] promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]; [chrysene co-treated with Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene] results in increased expression of CYP1A1 mRNA; [chrysene co-treated with Benzo(a)pyrene co-treated with benz(a)anthracene] results in increased expression of CYP1A1 mRNA; [chrysene co-treated with Benzo(a)pyrene] results in increased expression of CYP1A1 mRNA; chrysene inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]
chrysene results in increased expression of CYP1A1 mRNA; chrysene results in increased expression of CYP1A1 protein
chrysene results in increased activity of CYP1A1 protein
chrysene results in decreased expression of CYP1A1 mRNA

PMID:7750161 PMID:8961944 PMID:10190573 PMID:12107646 PMID:12117779 More...

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions
increases expression

[CYP1A2 protein co-treated with Trichloroepoxypropane] results in increased metabolism of chrysene; EPHX1 protein promotes the reaction [CYP1A2 protein results in increased metabolism of chrysene]
[CYP1A2 protein co-treated with Trichloroepoxypropane] results in increased metabolism of chrysene; [fluoranthene co-treated with pyrene co-treated with benz(a)anthracene co-treated with chrysene co-treated with benzo(b)fluoranthene co-treated with benzo(k)fluoranthene co-treated with Benzo(a)pyrene] results in increased expression of CYP1A2 mRNA; EPHX1 protein promotes the reaction [CYP1A2 protein results in increased metabolism of chrysene]
chrysene results in increased expression of CYP1A2 mRNA
[chrysene co-treated with Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene] results in increased expression of CYP1A2 mRNA; [chrysene co-treated with Benzo(a)pyrene co-treated with benz(a)anthracene] results in increased expression of CYP1A2 mRNA; [chrysene co-treated with Benzo(a)pyrene] results in increased expression of CYP1A2 mRNA

PMID:7750161 PMID:8961944 PMID:12107646 PMID:17253728 PMID:31087746 More...

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 1, subfamily b, polypeptide 1

multiple interactions
increases expression

[benz(a)anthracene co-treated with benzo(b)fluoranthene] promotes the reaction [chrysene promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA]]; [chrysene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene] promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA]; [chrysene co-treated with benz(a)anthracene] promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA]; [chrysene co-treated with Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene] results in increased expression of CYP1B1 mRNA; [chrysene co-treated with Benzo(a)pyrene co-treated with benz(a)anthracene] results in increased expression of CYP1B1 mRNA; [chrysene co-treated with Benzo(a)pyrene] results in increased expression of CYP1B1 mRNA; chrysene inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA]; chrysene promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA]
chrysene results in increased expression of CYP1B1 mRNA
chrysene results in increased expression of CYP1B1 mRNA; chrysene results in increased expression of CYP1B1 protein
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CYP1B1 mRNA

PMID:12107646 PMID:12117779 PMID:15315710 PMID:15566942 PMID:17253728 More...

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 2, subfamily e, polypeptide 1

increases expression

chrysene results in increased expression of CYP2E1 mRNA

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cystin 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of CYS1 mRNA

NCBI chr 6:41,300,836...41,318,071
Ensembl chr 6:41,300,836...41,318,071

G

cysteine rich tail 1

increases expression

chrysene results in increased expression of CYSRT1 mRNA

NCBI chr 3:8,054,195...8,057,846
Ensembl chr 3:8,053,482...8,059,721

G

differentiation antagonizing non-protein coding RNA

increases expression

chrysene results in increased expression of DANCR mRNA

NCBI chr14:34,126,956...34,127,936

G

aspartyl-tRNA synthetase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DARS1 mRNA

NCBI chr13:39,857,936...39,913,055
Ensembl chr13:39,857,936...39,913,116

G

D-box binding PAR bZIP transcription factor

increases expression
multiple interactions

chrysene results in increased expression of DBP mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DBP mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:96,175,796...96,180,745
Ensembl chr 1:96,175,440...96,180,745

G

DDB1 and CUL4 associated factor 12-like 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DCAF12L2 mRNA

NCBI chr X:123,293,761...123,296,550
Ensembl chr X:123,294,744...123,296,156

G

DDB1 and CUL4 associated factor 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DCAF4 mRNA

NCBI chr 6:103,154,847...103,180,992
Ensembl chr 6:103,154,867...103,180,982

G

DCC netrin 1 receptor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DCC mRNA

NCBI chr18:64,868,987...65,972,783
Ensembl chr18:64,873,898...65,972,740

G

decorin

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DCN mRNA

NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270

G

dimethylarginine dimethylaminohydrolase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DDAH1 mRNA

NCBI chr 2:234,667,499...234,800,322
Ensembl chr 2:234,667,491...234,799,339

G

dopa decarboxylase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DDC mRNA

NCBI chr14:86,378,685...86,469,189
Ensembl chr14:86,378,685...86,469,208

G

DNA damage-induced apoptosis suppressor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DDIAS mRNA

NCBI chr 1:146,906,150...146,930,462
Ensembl chr 1:146,906,154...146,930,462

G

DNA-damage-inducible transcript 4-like

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DDIT4L mRNA

NCBI chr 2:226,128,273...226,131,044
Ensembl chr 2:226,128,276...226,131,375

G

DEAD-box helicase 25

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DDX25 mRNA

NCBI chr 8:33,894,224...33,910,377
Ensembl chr 8:33,894,232...33,921,764

G

DEAD-box helicase 5

increases expression
multiple interactions

chrysene results in increased expression of DDX5 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DDX5 mRNA

PMID:26377693 PMID:27858113

NCBI chr10:91,723,508...91,732,210
Ensembl chr10:91,723,508...91,732,283

G

DEF6 guanine nucleotide exchange factor

increases expression

chrysene results in increased expression of DEF6 mRNA

NCBI chr20:6,268,579...6,290,030
Ensembl chr20:6,268,601...6,289,961

G

diacylglycerol O-acyltransferase 2

increases expression
multiple interactions

chrysene results in increased expression of DGAT2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DGAT2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:153,454,078...153,484,432
Ensembl chr 1:153,454,080...153,484,428

G

diacylglycerol kinase, alpha

increases expression

chrysene results in increased expression of DGKA mRNA

NCBI chr 7:1,148,734...1,175,324
Ensembl chr 7:1,148,735...1,175,110

G

diacylglycerol kinase, theta

increases expression

chrysene results in increased expression of DGKQ mRNA

NCBI chr14:1,059,125...1,073,131
Ensembl chr14:1,059,170...1,073,131

G

diaphanous-related formin 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DIAP1 mRNA

NCBI chr18:29,669,659...29,769,070
Ensembl chr18:29,669,659...29,769,172

G

dicer 1 ribonuclease III

increases expression

chrysene results in increased expression of DICER1 mRNA

NCBI chr 6:123,627,529...123,692,278
Ensembl chr 6:123,631,250...123,693,965

G

death inducer-obliterator 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DIDO1 mRNA

NCBI chr 3:167,772,535...167,825,894
Ensembl chr 3:167,772,770...167,817,218

G

divergent protein kinase domain 1B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DIPK1B mRNA

NCBI chr 3:9,455,914...9,464,169
Ensembl chr 3:9,456,409...9,464,161

G

DIX domain containing 1

decreases expression

chrysene results in decreased expression of DIXDC1 mRNA

NCBI chr 8:51,007,835...51,081,191
Ensembl chr 8:51,007,838...51,081,090

G

cyclin D binding myb-like transcription factor 1

decreases expression

chrysene results in decreased expression of DMTF1 mRNA

NCBI chr 4:24,909,937...24,950,786
Ensembl chr 4:24,910,534...24,950,967

G

DnaJ heat shock protein family (Hsp40) member A1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DNAJA1 mRNA

NCBI chr 5:55,842,414...55,853,326
Ensembl chr 5:55,842,426...55,853,967

G

DnaJ heat shock protein family (Hsp40) member B4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DNAJB4 mRNA

NCBI chr 2:241,129,346...241,159,272
Ensembl chr 2:241,130,340...241,159,089

G

DnaJ heat shock protein family (Hsp40) member B5

increases expression

chrysene results in increased expression of DNAJB5 mRNA

NCBI chr 5:57,176,840...57,186,067
Ensembl chr 5:57,176,845...57,185,490

G

DnaJ heat shock protein family (Hsp40) member C8

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DNAJC8 mRNA

NCBI chr 5:144,745,055...144,763,106
Ensembl chr 5:144,745,036...144,763,108

G

dynamin 2

increases expression

chrysene results in increased expression of DNM2 mRNA

NCBI chr 8:19,978,313...20,060,162
Ensembl chr 8:19,978,400...20,060,157

G

dolichyldiphosphatase 1

increases expression

chrysene results in increased expression of DOLPP1 mRNA

NCBI chr 3:13,666,000...13,674,312
Ensembl chr 3:13,665,823...13,674,311

G

denticleless E3 ubiquitin protein ligase homolog

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of DTL mRNA

NCBI chr13:103,115,810...103,155,029
Ensembl chr13:103,117,186...103,154,890

G

deltex E3 ubiquitin ligase 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DTX4 mRNA

NCBI chr 1:209,457,719...209,545,163
Ensembl chr 1:209,460,735...209,492,818

G

dual specificity phosphatase 3

decreases expression

chrysene results in decreased expression of DUSP3 mRNA

NCBI chr10:86,920,014...86,933,739
Ensembl chr10:86,920,014...86,933,962

G

dishevelled segment polarity protein 3

decreases expression
multiple interactions

chrysene results in decreased expression of DVL3 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DVL3 mRNA

PMID:26377693 PMID:27858113

NCBI chr11:80,365,446...80,382,641
Ensembl chr11:80,366,117...80,382,462

G

DAZ interacting zinc finger protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of DZIP1 mRNA

NCBI chr15:95,956,329...96,009,994
Ensembl chr15:95,956,398...96,010,066

G

extracellular matrix protein 1

increases expression
multiple interactions

chrysene results in increased expression of ECM1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ECM1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 2:183,287,491...183,292,729
Ensembl chr 2:183,287,322...183,292,671

G

endothelin receptor type B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of EDNRB mRNA

NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115

G

EF-hand domain family, member D1

increases expression

chrysene results in increased expression of EFHD1 mRNA

NCBI chr 9:87,938,259...87,984,917
Ensembl chr 9:87,938,284...87,984,917

G

ephrin A1

increases expression

chrysene results in increased expression of EFNA1 mRNA

NCBI chr 2:174,681,676...174,689,061
Ensembl chr 2:174,681,682...174,690,866

G

ephrin B1

decreases expression
multiple interactions

chrysene results in decreased expression of EFNB1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of EFNB1 mRNA

PMID:26377693 PMID:27858113

NCBI chr X:64,257,351...64,270,158
Ensembl chr X:64,257,351...64,270,157

G

embryonal Fyn-associated substrate

increases expression

chrysene results in increased expression of EFS mRNA

NCBI chr15:28,392,417...28,403,016
Ensembl chr15:28,392,187...28,401,902

G

EH domain binding protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of EHBP1 mRNA

NCBI chr14:96,093,327...96,380,502
Ensembl chr14:96,093,327...96,345,332

G

EH-domain containing 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EHD1 mRNA

NCBI chr 1:203,579,850...203,602,226
Ensembl chr 1:203,579,869...203,602,212

G

EH-domain containing 4

increases expression
multiple interactions

chrysene results in increased expression of EHD4 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EHD4 mRNA

PMID:26377693 PMID:27858113

NCBI chr 3:107,058,191...107,121,985
Ensembl chr 3:107,058,958...107,122,002

G

eukaryotic translation initiation factor 1

increases expression

chrysene results in increased expression of EIF1 mRNA

NCBI chr10:85,246,751...85,248,842
Ensembl chr10:85,246,764...85,427,327

G

eukaryotic translation initiation factor 3, subunit D

increases expression

chrysene results in increased expression of EIF3D mRNA

NCBI chr 7:109,539,795...109,552,184
Ensembl chr 7:109,539,356...109,552,206

G

eukaryotic translation initiation factor 4E binding protein 3

increases expression

chrysene results in increased expression of EIF4EBP3 mRNA

NCBI chr18:28,263,089...28,268,033
Ensembl chr18:28,162,311...28,268,024

G

eukaryotic translation initiation factor 4 gamma 1

increases expression

chrysene results in increased expression of EIF4G1 mRNA

NCBI chr11:80,221,919...80,241,958
Ensembl chr11:80,221,919...80,241,941

G

eukaryotic translation initiation factor 4 gamma, 3

increases expression

chrysene results in increased expression of EIF4G3 mRNA

NCBI chr 5:150,197,410...150,418,862
Ensembl chr 5:150,195,226...150,418,363

G

endomucin

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EMCN mRNA

NCBI chr 2:225,891,100...225,970,932
Ensembl chr 2:225,891,100...225,970,929

G

EMAP like 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EML1 mRNA

NCBI chr 6:127,283,968...127,457,246
Ensembl chr 6:127,284,029...127,457,246

G

erythrocyte membrane protein band 4.1

decreases expression
multiple interactions

chrysene results in decreased expression of EPB41 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of EPB41 mRNA

PMID:26377693 PMID:27858113

NCBI chr 5:144,110,010...144,264,037
Ensembl chr 5:144,111,906...144,237,821

G

Eph receptor A1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EPHA1 mRNA

NCBI chr 4:71,246,409...71,260,920
Ensembl chr 4:71,246,409...71,260,846

G

epoxide hydrolase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EPHX1 mRNA; EPHX1 protein promotes the reaction [CYP1A1 protein results in increased metabolism of chrysene]; EPHX1 protein promotes the reaction [CYP1A2 protein results in increased metabolism of chrysene]

PMID:8961944 PMID:27858113

NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235

G

erythropoietin receptor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EPOR mRNA

NCBI chr 8:20,489,678...20,494,257
Ensembl chr 8:20,489,678...20,494,257

G

ermin

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ERMN mRNA

NCBI chr 3:42,628,160...42,633,816
Ensembl chr 3:42,626,309...42,633,744

G

estrogen receptor 1

multiple interactions
increases expression

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with chrysene] results in increased expression of ESR1 mRNA
chrysene results in increased expression of ESR1 mRNA

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

EWS RNA-binding protein 1

decreases expression

chrysene results in decreased expression of EWSR1 mRNA

NCBI chr14:79,965,365...79,994,108
Ensembl chr14:79,965,368...79,994,544

G

exocyst complex component 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of EXOC4 mRNA

NCBI chr 4:61,807,706...62,584,316
Ensembl chr 4:61,807,761...62,585,723

G

exocyst complex component 6B

increases expression

chrysene results in increased expression of EXOC6B mRNA

NCBI chr 4:117,094,741...117,550,221
Ensembl chr 4:117,094,741...117,550,180

G

coagulation factor XIII A1 chain

increases expression

chrysene results in increased expression of F13A1 mRNA

NCBI chr17:27,815,723...27,992,494
Ensembl chr17:27,815,702...27,992,700

G

coagulation factor V

increases expression

chrysene results in increased expression of F5 mRNA

NCBI chr13:76,513,509...76,583,106
Ensembl chr13:76,513,255...76,582,317

G

family with sequence similarity 107, member A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of FAM107A mRNA

NCBI chr15:16,608,362...16,630,398
Ensembl chr15:16,607,205...16,630,396

G

family with sequence similarity 110, member D

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FAM110D mRNA

NCBI chr 5:146,471,048...146,474,019
Ensembl chr 5:146,471,049...146,474,056

G

family with sequence similarity 133, member B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FAM133B mRNA

NCBI chr 4:30,589,646...30,616,291
Ensembl chr 4:30,589,635...30,616,040

G

family with sequence similarity 13, member C

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FAM13C mRNA

NCBI chr20:18,065,625...18,187,792
Ensembl chr20:18,065,628...18,187,592

G

FAM20B, glycosaminoglycan xylosylkinase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FAM20B mRNA

NCBI chr13:68,801,663...68,839,979
Ensembl chr13:68,801,669...68,839,915

G

FERM, ARH/RhoGEF and pleckstrin domain protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FARP1 mRNA

NCBI chr15:98,124,304...98,363,299
Ensembl chr15:98,182,329...98,363,299

G

Fas-activated serine/threonine kinase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FASTK mRNA

NCBI chr 4:10,732,273...10,736,332
Ensembl chr 4:10,732,256...10,737,430

G

FAT atypical cadherin 2

increases expression

chrysene results in increased expression of FAT2 mRNA

NCBI chr10:39,364,072...39,456,324
Ensembl chr10:39,364,073...39,456,216

G

F-box protein 2

decreases expression

chrysene results in decreased expression of FBXO2 mRNA

NCBI chr 5:158,592,926...158,598,355
Ensembl chr 5:158,592,925...158,598,355

G

Fc epsilon receptor II

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of FCER2A mRNA

NCBI chr12:1,742,809...1,754,476
Ensembl chr12:1,742,815...1,754,476

G

ferredoxin-fold anticodon binding domain containing 1

increases expression

chrysene results in increased expression of FDXACB1 mRNA

NCBI chr 8:51,111,831...51,118,253
Ensembl chr 8:51,113,397...51,118,308

G

fibroblast growth factor 9

increases expression

chrysene results in increased expression of FGF9 mRNA

NCBI chr15:32,208,993...32,254,952
Ensembl chr15:32,210,074...32,253,309

G

FGFR1 oncogene partner 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FGFR1OP2 mRNA

NCBI chr 4:179,491,602...179,512,630
Ensembl chr 4:179,491,599...179,512,630

G

fibroblast growth factor receptor 3

increases expression

chrysene results in increased expression of FGFR3 mRNA

NCBI chr14:76,987,242...77,002,671
Ensembl chr14:76,987,993...77,003,341

G

forkhead associated phosphopeptide binding domain 1

increases expression

chrysene results in increased expression of FHAD1 mRNA

NCBI chr 5:154,191,593...154,310,442
Ensembl chr 5:154,191,745...154,310,354

G

fin bud initiation factor homolog

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FIBIN mRNA

NCBI chr 3:96,942,405...96,944,676
Ensembl chr 3:96,942,406...96,944,676

G

FIG4 phosphoinositide 5-phosphatase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of FIG4 mRNA

NCBI chr20:44,600,603...44,724,047
Ensembl chr20:44,600,603...44,723,844

G

fidgetin-like 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of FIGNL1 mRNA

NCBI chr14:86,368,670...86,381,728
Ensembl chr14:86,368,675...86,377,455

G

FKBP prolyl isomerase 1A

decreases expression
multiple interactions

chrysene results in decreased expression of FKBP1A mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FKBP1A mRNA

PMID:26377693 PMID:27858113

NCBI chr 3:140,040,359...140,060,107
Ensembl chr 3:140,040,278...140,060,743

G

FKBP prolyl isomerase 3

increases expression

chrysene results in increased expression of FKBP3 mRNA

NCBI chr 6:83,113,885...83,125,500
Ensembl chr 6:83,113,786...83,127,011

G

FLII, actin remodeling protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FLII mRNA

NCBI chr10:45,394,032...45,408,051
Ensembl chr10:45,394,032...45,407,970

G

flavin containing dimethylaniline monoxygenase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FMO1 mRNA

NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647

G

fragile X messenger ribonucleoprotein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FMR1 mRNA

NCBI chr X:147,240,239...147,278,057
Ensembl chr X:147,240,301...147,278,050

G

fibronectin type III domain containing 1

increases expression
multiple interactions

chrysene results in increased expression of FNDC1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FNDC1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:47,281,839...47,364,247
Ensembl chr 1:47,281,844...47,364,259

G

Fos proto-oncogene, AP-1 transcription factor subunit

increases expression

chrysene results in increased expression of FOS mRNA

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

forkhead box F1

increases expression
multiple interactions

chrysene results in increased expression of FOXF1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of FOXF1 mRNA

PMID:26377693 PMID:27858113

NCBI chr19:49,153,949...49,157,741
Ensembl chr19:49,153,699...49,157,738

G

forkhead box S1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FOXS1 mRNA

NCBI chr 3:141,397,012...141,398,296
Ensembl chr 3:141,397,016...141,398,281

G

FSHD region gene 1

decreases expression
multiple interactions

chrysene results in decreased expression of FRG1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FRG1 mRNA

PMID:26377693 PMID:27858113

NCBI chr16:50,925,783...50,946,661
Ensembl chr16:50,925,803...50,946,661

G

FERM domain containing 4B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FRMD4B mRNA

NCBI chr 4:129,895,401...130,222,070
Ensembl chr 4:129,895,708...130,084,197

G

fascin actin-bundling protein 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FSCN3 mRNA

NCBI chr 4:57,042,797...57,052,224
Ensembl chr 4:57,042,797...57,052,404

G

FMR1 autosomal homolog 2

increases expression

chrysene results in increased expression of FXR2 mRNA

NCBI chr10:54,350,577...54,370,964
Ensembl chr10:54,350,131...54,370,964

G

FXYD domain-containing ion transport regulator 3

increases expression

chrysene results in increased expression of FXYD3 mRNA

NCBI chr 1:86,305,531...86,312,455

G

gamma-aminobutyric acid type A receptor subunit alpha 3

increases expression

chrysene results in increased expression of GABRA3 mRNA

NCBI chr X:150,244,745...150,501,566
Ensembl chr X:150,261,607...150,501,559

G

growth arrest specific 6

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GAS6 mRNA

NCBI chr16:76,045,430...76,075,904
Ensembl chr16:76,045,426...76,075,904

G

golgi associated kinase 1B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GASK1B mRNA

NCBI chr 2:165,047,689...165,112,479
Ensembl chr 2:165,047,684...165,112,477

G

GATA binding protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GATA2 mRNA

NCBI chr 4:120,654,205...120,667,763
Ensembl chr 4:120,658,986...120,667,761

G

GATA zinc finger domain containing 2A

increases expression

chrysene results in increased expression of GATAD2A mRNA

NCBI chr16:19,429,578...19,520,320
Ensembl chr16:19,429,578...19,519,587

G

glucagon receptor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GCGR mRNA

NCBI chr10:105,808,474...105,816,641
Ensembl chr10:105,808,473...105,816,640

G

GTP cyclohydrolase 1

decreases expression

chrysene results in decreased expression of GCH1 mRNA

NCBI chr15:20,404,267...20,437,727
Ensembl chr15:20,402,527...20,437,698

G

glial cells missing transcription factor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GCM1 mRNA

NCBI chr 8:78,925,687...78,938,924
Ensembl chr 8:78,925,687...78,938,924

G

GCN1 activator of EIF2AK4

increases expression

chrysene results in increased expression of GCN1 mRNA

NCBI chr12:40,991,512...41,052,661
Ensembl chr12:40,991,512...41,052,555

G

guanine deaminase

increases expression

chrysene results in increased expression of GDA mRNA

NCBI chr 1:218,903,045...218,982,360
Ensembl chr 1:218,906,815...218,982,416

G

growth differentiation factor 15

decreases expression
multiple interactions

chrysene results in decreased expression of GDF15 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GDF15 mRNA

PMID:26377693 PMID:27858113

NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055

G

GDNF family receptor alpha 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GFRA4 mRNA

NCBI chr 3:118,254,937...118,262,252
Ensembl chr 3:118,255,402...118,258,329

G

gap junction protein, beta 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GJB1 mRNA

NCBI chr X:66,501,848...66,509,783
Ensembl chr X:66,501,820...66,509,925

G

GLIS family zinc finger 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GLIS2 mRNA

NCBI chr10:10,951,157...10,978,524
Ensembl chr10:10,951,371...10,971,578

G

geminin, DNA replication inhibitor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GMNN mRNA

NCBI chr17:40,301,771...40,310,054
Ensembl chr17:40,301,808...40,310,054

G

G protein subunit alpha i1

increases expression

chrysene results in increased expression of GNAI1 mRNA

NCBI chr 4:16,814,000...16,898,119
Ensembl chr 4:16,814,001...16,896,417

G

G patch domain containing 1

affects expression

chrysene affects the expression of GPATCH1 mRNA

NCBI chr 1:87,925,606...87,974,544
Ensembl chr 1:87,925,618...87,974,544

G

glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GPIHBP1 mRNA

NCBI chr 7:107,285,584...107,288,702
Ensembl chr 7:107,285,654...107,288,702

G

G protein-coupled receptor 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GPR4 mRNA

NCBI chr 1:78,865,376...78,877,126
Ensembl chr 1:78,865,409...78,876,599

G

GPRIN family member 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GPRIN3 mRNA

NCBI chr 4:88,572,062...88,657,369
Ensembl chr 4:88,563,607...88,657,429

G

growth factor receptor bound protein 10

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GRB10 mRNA

NCBI chr14:86,495,051...86,602,800
Ensembl chr14:86,495,054...86,602,806

G

growth regulating estrogen receptor binding 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of GREB1 mRNA

NCBI chr 6:39,440,522...39,562,364
Ensembl chr 6:39,440,504...39,581,633

G

galectin-related inter-fiber protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GRIFIN mRNA

NCBI chr12:14,080,170...14,082,892
Ensembl chr12:14,080,910...14,082,877

G

GRIP1 associated protein 1

increases expression

chrysene results in increased expression of GRIPAP1 mRNA

NCBI chr X:14,678,896...14,708,747
Ensembl chr X:14,678,898...14,708,679

G

gastrin releasing peptide

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GRP mRNA

NCBI chr18:59,388,679...59,402,061
Ensembl chr18:59,388,274...59,402,061

G

glutathione S-transferase mu 1

multiple interactions

GSTM1 protein affects the metabolism of [chrysene co-treated with Glutathione]

NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411

G

general transcription factor IIIC subunit 1

increases expression

chrysene results in increased expression of GTF3C1 mRNA

NCBI chr 1:180,203,995...180,270,201
Ensembl chr 1:180,203,995...180,270,201

G

granzyme A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of GZMA mRNA

NCBI chr 2:44,740,569...44,752,502
Ensembl chr 2:44,740,569...44,752,493

G

H19 imprinted maternally expressed transcript

increases expression

chrysene results in increased expression of H19 mRNA

NCBI chr 1:197,730,698...197,733,374
Ensembl chr 1:197,730,698...197,733,134

G

H1.1 linker histone, cluster member

decreases expression

chrysene results in decreased expression of H1F1 mRNA

NCBI chr17:41,366,268...41,367,011
Ensembl chr17:41,366,268...41,367,011

G

H1.2 linker histone, cluster member

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of H1F2 mRNA

NCBI chr17:41,391,106...41,392,597
Ensembl chr17:41,388,477...41,392,635

G

H1.4 linker histone, cluster member

decreases expression
multiple interactions

chrysene results in decreased expression of H1F4 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of H1F4 mRNA

PMID:26377693 PMID:27858113

NCBI chr17:41,486,574...41,487,355
Ensembl chr17:41,486,560...41,487,403

G

hydroxyacyl glutathione hydrolase

decreases expression

chrysene results in decreased expression of HAGH mRNA

NCBI chr10:13,874,883...13,889,527
Ensembl chr10:13,875,241...13,889,504

G

HEAT repeat containing 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HEATR1 mRNA

NCBI chr17:58,053,288...58,093,895
Ensembl chr17:58,051,700...58,093,948

G

HECT and RLD domain containing E3 ubiquitin protein ligase 4

increases expression

chrysene results in increased expression of HERC4 mRNA

NCBI chr20:25,329,972...25,404,657
Ensembl chr20:25,330,280...25,404,657

G

HIC ZBTB transcriptional repressor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of HIC1 mRNA

NCBI chr10:60,014,520...60,019,475
Ensembl chr10:60,011,528...60,019,475

G

hypoxia inducible lipid droplet-associated

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HILPDA mRNA

NCBI chr 4:57,871,088...57,874,048
Ensembl chr 4:57,871,110...57,874,557

G

HLF transcription factor, PAR bZIP family member

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of HLF mRNA

NCBI chr10:75,154,244...75,211,884
Ensembl chr10:75,154,507...75,211,935

G

histocompatibility minor 13

decreases expression
multiple interactions

chrysene results in decreased expression of H13 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of H13 mRNA

PMID:26377693 PMID:27858113

NCBI chr 3:141,145,792...141,183,557
Ensembl chr 3:141,145,782...141,184,703

G

homeobox containing 1

decreases expression

chrysene results in decreased expression of HMBOX1 mRNA

NCBI chr15:39,067,805...39,200,633
Ensembl chr15:39,067,804...39,200,323

G

hemicentin 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HMCN1 mRNA

NCBI chr13:62,615,461...63,084,524
Ensembl chr13:62,615,461...63,084,524

G

hemicentin 2

increases expression

chrysene results in increased expression of HMCN2 mRNA

NCBI chr 3:14,588,353...14,738,320
Ensembl chr 3:14,588,662...14,738,025

G

high mobility group box 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HMGB1 mRNA

NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565

G

high mobility group nucleosome binding domain 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HMGN5 mRNA

NCBI chr X:74,085,871...74,094,488
Ensembl chr X:74,085,875...74,094,441

G

hyaluronan-mediated motility receptor

decreases expression

chrysene results in decreased expression of HMMR mRNA

NCBI chr10:25,132,933...25,163,029
Ensembl chr10:25,132,977...25,163,060

G

heterogeneous nuclear ribonucleoprotein A/B

increases expression

chrysene results in increased expression of HNRNPAB mRNA

NCBI chr10:35,857,040...35,862,935
Ensembl chr10:35,857,041...35,863,344

G

heterogeneous nuclear ribonucleoprotein F

increases expression
multiple interactions

chrysene results in increased expression of HNRNPF mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HNRNPF mRNA

PMID:26377693 PMID:27858113

NCBI chr 4:151,083,262...151,104,464
Ensembl chr 4:151,083,062...151,109,038

G

heterogeneous nuclear ribonucleoprotein H1

increases expression

chrysene results in increased expression of HNRNPH1 mRNA

NCBI chr10:34,692,868...34,702,849
Ensembl chr10:34,693,555...34,702,846

G

HPS1, biogenesis of lysosomal organelles complex 3 subunit 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of HPS1 mRNA

NCBI chr 1:241,551,180...241,577,292
Ensembl chr 1:241,551,175...241,577,268

G

HR, lysine demethylase and nuclear receptor corepressor

increases expression

chrysene results in increased expression of HR mRNA

NCBI chr15:45,626,835...45,646,313
Ensembl chr15:45,626,835...45,646,313

G

hydroxysteroid (17-beta) dehydrogenase 14

increases expression

chrysene results in increased expression of HSD17B14 mRNA

NCBI chr 1:96,029,224...96,039,577
Ensembl chr 1:96,029,284...96,039,883

G

heat shock protein family A (Hsp70) member 1A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HSPA1A mRNA

NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227

G

HIV-1 Tat interactive protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of HTATIP2 mRNA

NCBI chr 1:99,473,411...99,488,632
Ensembl chr 1:99,469,245...99,488,629

G

HIV-1 Tat specific factor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of HTATSF1 mRNA

NCBI chr X:134,935,426...134,949,607
Ensembl chr X:134,935,426...134,949,607

G

hormonally upregulated Neu-associated kinase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of HUNK mRNA

NCBI chr11:29,641,122...29,758,392
Ensembl chr11:29,640,775...29,757,526

G

islet cell autoantigen 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ICA1 mRNA

NCBI chr 4:36,656,475...36,804,705
Ensembl chr 4:36,656,475...36,804,298

G

intercellular adhesion molecule 1

increases expression

chrysene results in increased expression of ICAM1 protein

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

inducible T-cell co-stimulator ligand

increases expression

chrysene results in increased expression of ICOSL mRNA

NCBI chr20:10,600,420...10,610,718
Ensembl chr20:10,600,420...10,610,703

G

inhibitor of DNA binding 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ID1 mRNA

NCBI chr 3:141,210,666...141,212,420
Ensembl chr 3:141,211,267...141,212,419

G

immediate early response 3

increases expression

chrysene results in increased expression of IER3 mRNA

NCBI chr20:2,928,378...2,929,582
Ensembl chr20:2,928,378...2,929,583

G

immediate early response 5

decreases expression
multiple interactions

chrysene results in decreased expression of IER5 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of IER5 mRNA

PMID:26377693 PMID:27858113

NCBI chr13:67,270,134...67,272,226
Ensembl chr13:67,270,135...67,272,227

G

immunoglobulin superfamily, member 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of IGSF3 mRNA

NCBI chr 2:188,811,394...188,899,645
Ensembl chr 2:188,811,380...188,899,645

G

IK cytokine

increases expression

chrysene results in increased expression of IK mRNA

NCBI chr18:28,358,004...28,372,809
Ensembl chr18:28,357,977...28,378,832

G

IKAROS family zinc finger 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of IKZF4 mRNA

NCBI chr 7:1,063,283...1,102,940
Ensembl chr 7:1,056,890...1,084,341

G

interleukin 18 receptor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of IL18R1 mRNA

NCBI chr 9:42,727,416...42,760,971
Ensembl chr 9:42,727,869...42,760,715

G

interleukin 6

increases expression

chrysene results in increased expression of IL6 mRNA

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

interleukin enhancer binding factor 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ILF2 mRNA

NCBI chr 2:175,952,174...175,971,191
Ensembl chr 2:175,952,186...175,971,337

G

inflammation and lipid regulator with UBA-like and NBR1-like domains

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ILRUN mRNA

NCBI chr20:5,809,931...5,876,197
Ensembl chr20:5,809,936...5,876,012

G

inka box actin regulator 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of INKA2 mRNA

NCBI chr 2:193,185,275...193,200,643
Ensembl chr 2:193,185,275...193,200,642

G

INO80 complex subunit B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of INO80B mRNA

NCBI chr 4:115,627,907...115,631,069
Ensembl chr 4:115,627,908...115,631,456

G

IQ motif and Sec7 domain ArfGEF 1

decreases expression

chrysene results in decreased expression of IQSEC1 mRNA

NCBI chr 4:123,168,719...123,488,300
Ensembl chr 4:123,168,719...123,488,172

G

inositol 1,4,5-triphosphate receptor associated 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of IRAG2 mRNA

NCBI chr 4:178,088,902...178,143,569
Ensembl chr 4:178,088,507...178,143,557

G

interferon regulatory factor 2 binding protein-like

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of IRF2BPL mRNA

NCBI chr 6:106,527,179...106,531,294
Ensembl chr 6:106,528,053...106,530,401

G

integrin subunit alpha 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ITGA1 mRNA

NCBI chr 2:46,646,125...46,812,237
Ensembl chr 2:46,653,193...46,812,238

G

integrin subunit alpha 7

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ITGA7 mRNA

NCBI chr 7:1,360,125...1,388,886
Ensembl chr 7:1,359,940...1,388,450

G

integrin subunit alpha X

decreases expression

chrysene results in decreased expression of ITGAX mRNA

NCBI chr 1:182,709,653...182,740,709
Ensembl chr 1:182,719,609...182,740,698

G

integrin subunit beta 1

decreases expression

chrysene results in decreased expression of ITGB1 mRNA

NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195

G

inter-alpha-trypsin inhibitor heavy chain 5

increases expression

chrysene results in increased expression of ITIH5 mRNA

NCBI chr17:68,248,115...68,352,216
Ensembl chr17:68,252,128...68,352,207

G

inositol 1,4,5-trisphosphate receptor, type 2

increases expression

chrysene results in increased expression of ITPR2 mRNA

NCBI chr 4:179,028,594...179,434,657
Ensembl chr 4:179,027,281...179,404,164

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases expression

chrysene results in increased expression of JUN mRNA

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

JunB proto-oncogene, AP-1 transcription factor subunit

increases expression

chrysene results in increased expression of JUNB mRNA

NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035

G

KN motif and ankyrin repeat domains 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of KANK4 mRNA

NCBI chr 5:113,401,491...113,465,526
Ensembl chr 5:113,402,468...113,465,555

G

lysine acetyltransferase 14

increases expression

chrysene results in increased expression of KAT14 mRNA

NCBI chr 3:131,736,430...131,781,732
Ensembl chr 3:131,736,549...131,781,706

G

potassium voltage-gated channel subfamily E regulatory subunit 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of KCNE3 mRNA

NCBI chr 1:154,523,903...154,530,865
Ensembl chr 1:154,523,830...154,532,020

G

potassium channel tetramerization domain containing 15

increases expression

chrysene results in increased expression of KCTD15 mRNA

NCBI chr 1:87,258,658...87,271,979
Ensembl chr 1:87,258,658...87,273,497

G

KIAA0232 homolog

increases expression

chrysene results in increased expression of D5ERTD579E mRNA

NCBI chr14:74,094,421...74,159,316
Ensembl chr14:74,094,488...74,159,326

G

kinesin family member 26B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of KIF26B mRNA

NCBI chr13:90,282,821...90,689,058
Ensembl chr13:90,283,404...90,682,811

G

KIT ligand

decreases expression
multiple interactions

chrysene results in decreased expression of KITL mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of KITL mRNA

PMID:26377693 PMID:27858113

NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214

G

kelch-like family member 18

increases expression

chrysene results in increased expression of KLHL18 mRNA

NCBI chr 8:110,400,679...110,459,442
Ensembl chr 8:110,400,681...110,459,323

G

kelch-like family member 29

increases expression

chrysene results in increased expression of KLHL29 mRNA

NCBI chr 6:28,086,489...28,390,647
Ensembl chr 6:28,086,489...28,390,647

G

kelch-like family member 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of KLHL5 mRNA

NCBI chr14:43,144,254...43,206,192
Ensembl chr14:43,144,257...43,184,238

G

kelch-like family member 6

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of KLHL6 mRNA

NCBI chr11:80,970,917...81,010,593
Ensembl chr11:80,970,917...81,009,677

G

kallikrein 1-related peptidase C10

multiple interactions

alpha-naphthoflavone inhibits the reaction [chrysene inhibits the reaction [Dihydrotestosterone results in increased expression of KLK3 mRNA]]; alpha-naphthoflavone inhibits the reaction [chrysene inhibits the reaction [Dihydrotestosterone results in increased expression of KLK3 protein]]; chrysene inhibits the reaction [Dihydrotestosterone results in increased expression of KLK3 mRNA]; chrysene inhibits the reaction [Dihydrotestosterone results in increased expression of KLK3 protein]; Proadifen promotes the reaction [chrysene inhibits the reaction [Dihydrotestosterone results in increased expression of KLK3 protein]]

NCBI chr 1:94,402,993...94,407,052
Ensembl chr 1:94,402,993...94,407,052

G

lysine methyltransferase 2D

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of KMT2D mRNA

NCBI chr 7:129,980,744...130,022,088
Ensembl chr 7:129,962,887...130,020,325

G

lysine methyltransferase 5B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of KMT5B mRNA

NCBI chr 1:201,000,444...201,049,819
Ensembl chr 1:201,000,444...201,049,819

G

keratin 13

increases expression

chrysene results in increased expression of KRT13 mRNA

NCBI chr10:85,051,887...85,056,099
Ensembl chr10:85,051,889...85,056,084

G

keratin 15

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of KRT15 mRNA

NCBI chr10:85,066,797...85,070,614
Ensembl chr10:85,066,802...85,171,799

G

keratin 4

increases expression

chrysene results in increased expression of KRT4 mRNA

NCBI chr 7:133,046,067...133,052,027
Ensembl chr 7:133,046,515...133,052,019

G

keratinocyte associated protein 2

decreases expression

chrysene results in decreased expression of KRTCAP2 mRNA

NCBI chr 2:174,654,409...174,658,405
Ensembl chr 2:174,654,219...174,658,405

G

laminin subunit alpha 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LAMA1 mRNA

NCBI chr 9:107,692,770...107,816,847
Ensembl chr 9:107,692,770...107,817,478

G

laminin subunit alpha 5

increases expression

chrysene results in increased expression of LAMA5 mRNA

NCBI chr 3:167,270,296...167,318,370
Ensembl chr 3:167,270,296...167,318,451

G

laminin subunit beta 1

increases expression

chrysene results in increased expression of LAMB1 mRNA

NCBI chr 6:47,835,492...47,902,585
Ensembl chr 6:47,835,525...47,902,585

G

lysosomal protein transmembrane 4 alpha

decreases expression

chrysene results in decreased expression of LAPTM4A mRNA

NCBI chr 6:31,719,287...31,737,023
Ensembl chr 6:31,718,976...31,737,020

G

LARGE xylosyl- and glucuronyltransferase 2

increases expression

chrysene results in increased expression of LARGE2 mRNA

NCBI chr 3:78,334,627...78,347,167
Ensembl chr 3:78,336,056...78,342,184

G

La ribonucleoprotein 4B

increases expression

chrysene results in increased expression of LARP4B mRNA

NCBI chr17:61,138,663...61,217,423
Ensembl chr17:61,138,709...61,187,960

G

LIM and SH3 protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of LASP1 mRNA

NCBI chr10:82,795,177...82,835,659
Ensembl chr10:82,795,137...82,943,292

G

late cornified envelope 3E

increases expression

chrysene results in increased expression of LCE3B mRNA

NCBI chr 2:178,578,488...178,579,661
Ensembl chr 2:178,579,162...178,579,458

G

ligand dependent nuclear receptor corepressor-like

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of LCORL mRNA

NCBI chr14:65,271,339...65,407,732
Ensembl chr14:65,271,135...65,404,174

G

left right determination factor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LEFTY1 mRNA

NCBI chr13:92,649,226...92,659,722
Ensembl chr13:92,656,323...92,659,720

G

leptin receptor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LEPR mRNA

NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908

G

galectin 1

increases expression

chrysene results in increased expression of LGALS1 mRNA

NCBI chr 7:110,485,239...110,488,345
Ensembl chr 7:110,481,392...110,488,345

G

LHFPL tetraspan subfamily member 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of LHFPL3 mRNA

G

lipase A, lysosomal acid type

decreases expression

chrysene results in decreased expression of LIPA mRNA

NCBI chr 1:232,024,351...232,057,735
Ensembl chr 1:232,024,356...232,057,633

G

loricrin cornified envelope precursor protein

increases expression

chrysene results in increased expression of LORICRIN mRNA

NCBI chr 2:177,558,062...177,560,960
Ensembl chr 2:177,558,252...177,559,807

G

lipin 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LPIN1 mRNA

NCBI chr 6:39,309,198...39,417,034
Ensembl chr 6:39,312,748...39,417,097

G

leucine rich repeat containing 45

increases expression

chrysene results in increased expression of LRRC45 mRNA

NCBI chr10:105,994,468...106,002,425
Ensembl chr10:105,993,087...106,002,424

G

leucine rich repeat containing 75B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LRRC75B mRNA

NCBI chr20:13,100,302...13,106,503
Ensembl chr20:13,100,302...13,106,503

G

leucine rich repeat containing 8 VRAC subunit B

decreases expression

chrysene results in decreased expression of LRRC8B mRNA

NCBI chr14:4,350,462...4,416,336
Ensembl chr14:4,354,508...4,416,311

G

leucine-rich repeat kinase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of LRRK1 mRNA

NCBI chr 1:119,844,360...119,972,885
Ensembl chr 1:119,845,146...119,979,734

G

leucine rich repeat neuronal 4

increases expression

chrysene results in increased expression of LRRN4 mRNA

NCBI chr 3:120,138,093...120,150,877
Ensembl chr 3:120,139,410...120,150,831

G

leucine-rich repeats and transmembrane domains 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LRTM2 mRNA

NCBI chr 4:152,485,863...152,508,248
Ensembl chr 4:152,485,866...152,500,377

G

leukocyte specific transcript 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LST1 mRNA

NCBI chr20:3,634,680...3,639,731
Ensembl chr20:3,634,749...3,637,997

G

leukotriene C4 synthase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LTC4S mRNA

NCBI chr10:34,560,476...34,562,790
Ensembl chr10:34,560,360...34,562,651

G

LTV1 ribosome biogenesis factor

increases expression

chrysene results in increased expression of LTV1 mRNA

NCBI chr 1:7,565,673...7,578,398
Ensembl chr 1:7,565,669...7,578,563

G

lumican

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of LUM mRNA

NCBI chr 7:32,358,990...32,365,794
Ensembl chr 7:32,358,614...32,365,793

G

lymphocyte antigen 6 family member A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LY6A mRNA

NCBI chr 7:107,177,191...107,189,436
Ensembl chr 7:107,183,469...107,189,981

G

lymphatic vessel endothelial hyaluronan receptor 1

increases expression
multiple interactions

chrysene results in increased expression of LYVE1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of LYVE1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:164,962,872...164,976,309
Ensembl chr 1:164,962,872...164,976,309

G

leucine zipper tumor suppressor family member 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of LZTS3 mRNA

NCBI chr 3:117,850,286...117,861,132
Ensembl chr 3:117,851,702...117,860,081

G

membrane associated guanylate kinase, WW and PDZ domain containing 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MAGI3 mRNA

NCBI chr 2:191,514,726...191,717,048
Ensembl chr 2:191,518,506...191,716,735

G

magnesium transporter 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MAGT1 mRNA

NCBI chr X:71,038,489...71,079,704
Ensembl chr X:71,038,489...71,079,699

G

monoamine oxidase A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MAOA mRNA

NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593

G

mitogen-activated protein kinase kinase kinase kinase 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MAP4K4 mRNA

NCBI chr 9:42,200,708...42,326,708
Ensembl chr 9:42,200,278...42,326,698

G

macrophage receptor with collagenous structure

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MARCO mRNA

NCBI chr13:31,616,278...31,648,521
Ensembl chr13:31,616,278...31,648,521

G

MARVEL domain containing 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MARVELD3 mRNA

NCBI chr19:37,908,727...37,923,420
Ensembl chr19:37,905,638...37,923,420

G

methionine adenosyltransferase 1A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MAT1A mRNA

NCBI chr16:16,983,084...17,001,284
Ensembl chr16:16,983,022...17,001,274

G

methionine adenosyltransferase 2A

increases expression

chrysene results in increased expression of MAT2A mRNA

NCBI chr 4:104,489,877...104,495,447
Ensembl chr 4:104,488,466...104,495,493

G

membrane bound O-acyltransferase domain containing 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MBOAT2 mRNA

NCBI chr 6:41,471,135...41,597,599
Ensembl chr 6:41,471,161...41,593,485

G

melanoma cell adhesion molecule

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MCAM mRNA

NCBI chr 8:44,479,391...44,487,575
Ensembl chr 8:44,479,376...44,487,571

G

MDM2 proto-oncogene

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MDM2 mRNA

NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915

G

MDM4 regulator of p53

decreases expression
multiple interactions

chrysene results in decreased expression of MDM4 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MDM4 mRNA

PMID:26377693 PMID:27858113

NCBI chr13:44,432,596...44,516,165
Ensembl chr13:44,406,213...44,474,226

G

midasin AAA ATPase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MDN1 mRNA

NCBI chr 5:47,055,435...47,190,426
Ensembl chr 5:47,055,447...47,186,332

G

mediator complex subunit 10

decreases expression

chrysene results in decreased expression of MED10 mRNA

NCBI chr 1:33,470,064...33,481,698
Ensembl chr 1:33,470,066...33,475,767

G

mediator complex subunit 21

decreases expression

chrysene results in decreased expression of MED21 mRNA

NCBI chr 4:179,560,509...179,583,811
Ensembl chr 4:179,560,579...179,567,548

G

mediator complex subunit 24

increases expression

chrysene results in increased expression of MED24 mRNA

NCBI chr10:83,664,609...83,702,315
Ensembl chr10:83,664,609...83,690,123

G

mediator complex subunit 28

decreases expression

chrysene results in decreased expression of MED28 mRNA

NCBI chr14:65,594,785...65,603,583
Ensembl chr14:65,594,647...65,603,583

G

mediator complex subunit 7

decreases expression

chrysene results in decreased expression of MED7 mRNA

NCBI chr10:30,842,330...30,857,873
Ensembl chr10:30,842,292...30,859,220

G

myocyte enhancer factor 2C

increases expression

chrysene results in increased expression of MEF2C mRNA

NCBI chr 2:13,973,299...14,136,065
Ensembl chr 2:13,993,438...14,132,880

G

maternally expressed 3

increases expression

chrysene results in increased expression of MEG3 mRNA

NCBI chr 6:128,491,808...128,524,010

G

microfibril associated protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MFAP2 mRNA

NCBI chr 5:153,312,068...153,320,266
Ensembl chr 5:153,314,711...153,320,259

G

microfibril associated protein 4

increases expression
multiple interactions

chrysene results in increased expression of MFAP4 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MFAP4 mRNA

PMID:26377693 PMID:27858113

NCBI chr10:46,167,158...46,170,176
Ensembl chr10:46,167,217...46,170,155

G

MFSD2 lysolipid transporter A, lysophospholipid

increases expression

chrysene results in increased expression of MFSD2A mRNA

NCBI chr 5:135,225,801...135,240,744
Ensembl chr 5:135,225,816...135,240,690

G

alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MGAT2 mRNA

NCBI chr 6:87,656,360...87,658,849
Ensembl chr 6:87,656,349...87,658,177

G

monoglyceride lipase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MGLL mRNA

NCBI chr 4:121,192,186...121,294,187
Ensembl chr 4:121,192,195...121,294,179

G

O-6-methylguanine-DNA methyltransferase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MGMT mRNA

NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756

G

MIA SH3 domain containing

decreases expression

chrysene results in decreased expression of MIA mRNA

NCBI chr 1:82,473,677...82,476,378
Ensembl chr 1:82,473,678...82,475,370

G

MICAL-like 1

increases expression

chrysene results in increased expression of MICALL1 mRNA

NCBI chr 7:110,676,706...110,707,171
Ensembl chr 7:110,676,775...110,707,177

G

mitotic deacetylase associated SANT domain protein

multiple interactions
decreases expression

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MIDEAS mRNA
chrysene results in decreased expression of MIDEAS mRNA

PMID:26377693 PMID:27858113

NCBI chr 6:103,784,779...103,854,470
Ensembl chr 6:103,787,873...103,829,178

G

marker of proliferation Ki-67

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MKI67 mRNA

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

MTOR associated protein, LST8 homolog

increases expression

chrysene results in increased expression of MLST8 mRNA

NCBI chr10:13,498,377...13,504,128
Ensembl chr10:13,498,388...13,504,128

G

membrane magnesium transporter 1

decreases expression

chrysene results in decreased expression of MMGT1 mRNA

NCBI chr X:134,408,463...134,420,798
Ensembl chr X:134,408,466...134,420,729

G

matrix metallopeptidase 14

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MMP14 mRNA

NCBI chr15:27,887,795...27,897,020
Ensembl chr15:27,887,727...27,899,864

G

matrix metallopeptidase 8

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MMP8 mRNA

NCBI chr 8:4,724,009...4,733,864
Ensembl chr 8:4,724,029...4,733,520

G

multimerin 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MMRN2 mRNA

NCBI chr16:9,705,925...9,727,405
Ensembl chr16:9,705,892...9,727,405

G

mannose-P-dolichol utilization defect 1

decreases expression

chrysene results in decreased expression of MPDU1 mRNA

NCBI chr10:54,374,719...54,380,301
Ensembl chr10:54,374,725...54,380,447

G

macrophage expressed 1

decreases expression
multiple interactions

chrysene results in decreased expression of MPEG1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MPEG1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:209,452,176...209,456,692
Ensembl chr 1:209,452,133...209,458,855

G

MPV17 mitochondrial inner membrane protein like 2

decreases expression

chrysene results in decreased expression of MPV17L2 mRNA

NCBI chr16:18,680,106...18,684,212
Ensembl chr16:18,681,826...18,684,212

G

membrane spanning 4-domains A1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MS4A1 mRNA

NCBI chr 1:207,906,370...207,927,028
Ensembl chr 1:207,906,374...207,918,512

G

mesothelin

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MSLN mRNA

NCBI chr10:14,771,946...14,781,382
Ensembl chr10:14,771,961...14,777,643

G

macrophage scavenger receptor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MSR1 mRNA

NCBI chr16:52,717,775...52,803,602
Ensembl chr16:52,717,732...52,799,676

G

macrophage stimulating 1 receptor

increases expression

chrysene results in increased expression of MST1R mRNA

NCBI chr 8:108,596,100...108,611,441
Ensembl chr 8:108,597,299...108,612,455

G

mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ND4L mRNA

NCBI chr MT:9,870...10,166
NCBI chr MT:9,870...10,166
NCBI chr MT:9,870...10,166
NCBI chr MT:9,870...10,166
NCBI chr MT:9,870...10,166
Ensembl chr MT:9,870...10,166

G

mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ND6 mRNA

NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
Ensembl chr MT:13,543...14,061

G

metallothionein 1

increases expression

chrysene results in increased expression of MT1 mRNA

NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049
Ensembl chr17:10,826,032...10,827,049

G

metallothionein 2A

increases expression

chrysene results in increased expression of MT2 mRNA

NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784

G

mitochondrial fission regulator 1

decreases expression

chrysene results in decreased expression of MTFR1 mRNA

NCBI chr 2:101,678,331...101,713,547
Ensembl chr 2:101,679,265...101,713,544

G

methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MTHFD1L mRNA

NCBI chr 1:40,443,926...40,632,911
Ensembl chr 1:40,444,008...40,632,905

G

myotubularin related protein 10

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MTMR10 mRNA

NCBI chr 1:117,859,355...117,910,839
Ensembl chr 1:117,859,267...117,910,849

G

mucin 16, cell surface associated

increases expression

chrysene results in increased expression of MUC16 mRNA

NCBI chr 8:16,164,531...16,323,126

G

myeloid-associated differentiation marker

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of MYADM mRNA

NCBI chr 1:65,864,180...65,874,701
Ensembl chr 1:65,864,173...65,874,035

G

myosin binding protein C1

increases expression

chrysene results in increased expression of MYBPC1 mRNA

NCBI chr 7:22,930,350...23,015,981
Ensembl chr 7:22,930,350...23,015,957

G

myosin heavy chain 1

increases expression

chrysene results in increased expression of MYH1 mRNA

NCBI chr10:51,885,913...51,909,699
Ensembl chr10:51,885,913...51,946,295

G

myosin heavy chain 4

increases expression

chrysene results in increased expression of MYH4 mRNA

NCBI chr10:51,923,149...51,946,297
Ensembl chr10:51,885,913...51,946,295

G

myosin light chain 6

increases expression

chrysene results in increased expression of MYL6 mRNA

NCBI chr 7:910,764...914,062
Ensembl chr 7:910,774...933,791

G

myosin light chain kinase

increases expression

chrysene results in increased expression of MYLK mRNA

NCBI chr11:65,783,008...66,030,239
Ensembl chr11:65,783,008...66,030,261

G

myosin IG

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of MYO1G mRNA

NCBI chr14:81,386,701...81,401,843
Ensembl chr14:81,386,701...81,401,843

G

myomesin 3

increases expression

chrysene results in increased expression of MYOM3 mRNA

NCBI chr 5:147,992,737...148,043,282
Ensembl chr 5:147,992,737...148,043,274

G

myozenin 1

increases expression

chrysene results in increased expression of MYOZ1 mRNA

NCBI chr15:3,644,333...3,651,584
Ensembl chr15:3,644,368...3,652,884

G

N-acetyltransferase 8

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NAT8 mRNA

NCBI chr 4:118,279,521...118,284,671
Ensembl chr 4:118,270,954...118,281,763

G

neurobeachin-like 1

decreases expression

chrysene results in decreased expression of NBEAL1 mRNA

NCBI chr 9:61,575,154...61,743,896
Ensembl chr 9:61,575,356...61,736,750

G

non-SMC condensin I complex, subunit H

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NCAPH mRNA

NCBI chr 3:114,371,937...114,399,178
Ensembl chr 3:114,371,941...114,399,180

G

nuclear cap binding protein subunit 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NCBP2 mRNA

NCBI chr11:68,821,026...68,829,863
Ensembl chr11:68,817,740...68,851,885

G

nuclear cap binding subunit 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NCBP3 mRNA

NCBI chr10:57,665,716...57,695,432
Ensembl chr10:57,665,716...57,695,432

G

nuclear receptor coactivator 3

increases expression

chrysene results in increased expression of NCOA3 mRNA

NCBI chr 3:154,738,566...154,821,395
Ensembl chr 3:154,738,581...154,818,594

G

NDC80 kinetochore complex component

decreases expression

chrysene results in decreased expression of NDC80 mRNA

NCBI chr 9:111,407,191...111,440,921
Ensembl chr 9:111,407,191...111,440,924

G

NADH:ubiquinone oxidoreductase subunit B6

decreases expression

chrysene results in decreased expression of NDUFB6 mRNA

NCBI chr 5:55,400,543...55,410,110
Ensembl chr 5:55,400,543...55,410,181

G

nebulin

increases expression

chrysene results in increased expression of NEB mRNA

NCBI chr 3:36,613,677...36,811,618
Ensembl chr 3:36,613,716...36,811,574

G

nectin cell adhesion molecule 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PVRL1 mRNA

NCBI chr 8:44,101,776...44,164,863
Ensembl chr 8:44,101,776...44,189,787

G

neuraminidase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NEU2 mRNA

NCBI chr 9:88,218,494...88,267,356
Ensembl chr 9:88,249,135...88,267,355

G

nexilin (F actin binding protein)

increases expression

chrysene results in increased expression of NEXN mRNA

NCBI chr 2:241,186,783...241,218,315
Ensembl chr 2:241,186,790...241,218,342

G

nuclear factor of activated T-cells 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NFATC1 mRNA

NCBI chr18:74,046,422...74,156,041
Ensembl chr18:74,046,904...74,156,028

G

nuclear factor, erythroid 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NFE2 mRNA

NCBI chr 7:134,382,758...134,395,364
Ensembl chr 7:134,382,761...134,390,108

G

nuclear factor, interleukin 3 regulated

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NFIL3 mRNA

NCBI chr17:12,280,499...12,295,728
Ensembl chr17:12,280,484...12,295,858

G

NFKB inhibitor alpha

decreases expression

chrysene results in decreased expression of NFKBIA mRNA

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

nerve growth factor receptor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TNFRSF10B mRNA

NCBI chr10:80,515,287...80,533,518
Ensembl chr10:80,515,299...80,533,518

G

NHL repeat containing 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NHLRC2 mRNA

NCBI chr 1:255,589,743...255,648,904
Ensembl chr 1:255,589,742...255,651,408

G

NHS-like 1

increases expression

chrysene results in increased expression of NHSL1 mRNA

NCBI chr 1:12,956,525...13,188,580
Ensembl chr 1:12,956,021...13,187,547

G

natural killer cell triggering receptor

decreases expression
multiple interactions

chrysene results in decreased expression of NKTR mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NKTR mRNA

PMID:26377693 PMID:27858113

NCBI chr 8:121,380,010...121,420,495
Ensembl chr 8:121,382,436...121,418,314

G

NOC2-like nucleolar associated transcriptional repressor

increases expression

chrysene results in increased expression of NOC2L mRNA

NCBI chr 5:166,820,150...166,831,949
Ensembl chr 5:166,820,161...166,831,949

G

non-POU domain containing, octamer-binding

increases expression

chrysene results in increased expression of NONO mRNA

NCBI chr X:66,554,131...66,571,992
Ensembl chr X:66,554,098...66,571,952

G

NOP2 nucleolar protein

increases expression

chrysene results in increased expression of NOP2 mRNA

NCBI chr 4:157,932,731...157,944,462
Ensembl chr 4:157,932,716...157,944,459

G

notch receptor 1

decreases expression
multiple interactions

chrysene results in decreased expression of NOTCH1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NOTCH1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531

G

NADPH oxidase activator 1

decreases expression

chrysene results in decreased expression of NOXA1 mRNA

NCBI chr 3:7,895,488...7,907,011
Ensembl chr 3:7,895,488...7,905,967

G

nephrocystin 1

decreases expression
multiple interactions

chrysene results in decreased expression of NPHP1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NPHP1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 3:114,960,650...115,016,234
Ensembl chr 3:114,960,650...115,016,234

G

nucleophosmin 1

increases expression

chrysene results in increased expression of NPM1 mRNA

NCBI chr10:17,741,512...17,751,626
Ensembl chr10:17,739,941...17,751,645

G

natriuretic peptide receptor 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NPR3 mRNA

NCBI chr 2:60,865,483...60,933,432
Ensembl chr 2:60,870,594...60,932,955

G

neuropeptide Y receptor Y1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NPY1R mRNA

NCBI chr16:23,037,788...23,047,330
Ensembl chr16:23,037,789...23,046,759

G

NAD(P)H quinone dehydrogenase 1

increases activity

chrysene results in increased activity of NQO1 protein

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

nuclear receptor subfamily 1, group D, member 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NR1D1 mRNA

NCBI chr10:83,728,348...83,735,562
Ensembl chr10:83,728,318...83,735,705

G

nuclear receptor subfamily 1, group D, member 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NR1D2 mRNA

NCBI chr15:7,524,257...7,550,553
Ensembl chr15:7,524,257...7,550,553

G

nuclear receptor binding protein 2

increases expression

chrysene results in increased expression of NRBP2 mRNA

NCBI chr 7:107,798,642...107,805,225
Ensembl chr 7:107,799,497...107,805,230

G

neuronal cell adhesion molecule

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NRCAM mRNA

NCBI chr 6:61,402,813...61,698,536
Ensembl chr 6:61,329,863...61,702,992

G

nuclear receptor binding SET domain protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NSD1 mRNA

NCBI chr17:9,311,963...9,426,373
Ensembl chr17:9,315,237...9,425,358

G

NSFL1 cofactor

increases expression

chrysene results in increased expression of NSFL1C mRNA

NCBI chr 3:139,978,306...140,002,876
Ensembl chr 3:139,978,301...140,002,870

G

5'-nucleotidase domain containing 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of NT5DC2 mRNA

NCBI chr16:6,322,485...6,330,538
Ensembl chr16:6,322,236...6,330,537

G

netrin 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NTN1 mRNA

NCBI chr10:52,899,933...53,098,591
Ensembl chr10:52,899,934...53,085,326

G

nuclear FMR1 interacting protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NUFIP2 mRNA

NCBI chr10:62,574,922...62,607,729
Ensembl chr10:62,574,882...62,600,346

G

nucleoporin 85

increases expression

chrysene results in increased expression of NUP85 mRNA

NCBI chr10:100,806,482...100,825,029
Ensembl chr10:100,806,437...100,825,043

G

nuclear RNA export factor 1

increases expression

chrysene results in increased expression of NXF1 mRNA

NCBI chr 1:205,655,442...205,668,637
Ensembl chr 1:205,655,375...205,668,636

G

nucleoredoxin

increases expression

chrysene results in increased expression of NXN mRNA

NCBI chr10:61,109,322...61,247,578
Ensembl chr10:61,110,020...61,248,251

G

neurexophilin 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of NXPH3 mRNA

NCBI chr10:80,456,283...80,459,949
Ensembl chr10:80,455,429...80,462,415

G

O-GlcNAcase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of OGA mRNA

NCBI chr 1:244,598,285...244,633,835
Ensembl chr 1:244,598,292...244,634,359

G

purinergic receptor P2X 7

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of P2RX7 mRNA

NCBI chr12:33,889,709...33,934,168
Ensembl chr12:33,879,745...33,934,619

G

proliferation-associated 2G4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PA2G4 mRNA

NCBI chr 7:984,795...992,264
Ensembl chr 7:983,971...992,331

G

PABPN1 like

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PABPN1L mRNA

NCBI chr19:50,669,965...50,673,409
Ensembl chr19:50,669,967...50,673,366

G

PAF1 homolog, Paf1/RNA polymerase II complex component

increases expression

chrysene results in increased expression of PAF1 mRNA

NCBI chr 1:83,683,654...83,689,233
Ensembl chr 1:83,668,813...83,689,237

G

phenylalanine hydroxylase

decreases expression

chrysene results in decreased expression of PAH mRNA

NCBI chr 7:21,933,179...21,998,134
Ensembl chr 7:21,933,179...21,998,130

G

palmdelphin

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PALMD mRNA

NCBI chr 2:204,889,526...204,941,355
Ensembl chr 2:204,889,533...204,941,519

G

poly(A) specific ribonuclease subunit PAN3

increases expression

chrysene results in increased expression of PAN3 mRNA

NCBI chr12:7,476,707...7,595,384
Ensembl chr12:7,476,697...7,599,204

G

pantothenate kinase 4

increases expression

chrysene results in increased expression of PANK4 mRNA

NCBI chr 5:165,525,340...165,542,139
Ensembl chr 5:165,525,402...165,542,135

G

poly (A) polymerase alpha

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PAPOLA mRNA

NCBI chr 6:124,682,015...124,734,706
Ensembl chr 6:124,682,105...124,734,468

G

prostate androgen-regulated mucin-like protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PARM1 mRNA

NCBI chr14:16,468,309...16,577,339
Ensembl chr14:16,468,459...16,577,314

G

PDZ binding kinase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PBK mRNA

NCBI chr15:40,022,873...40,034,014
Ensembl chr15:40,023,002...40,034,014

G

PBX homeobox 1

decreases expression
multiple interactions

chrysene results in decreased expression of PBX1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PBX1 mRNA

PMID:26377693 PMID:27858113

NCBI chr13:80,278,766...80,588,563
Ensembl chr13:80,278,770...80,588,594

G

protocadherin 17

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PCDH17 mRNA

NCBI chr15:60,222,088...60,316,172
Ensembl chr15:60,222,004...60,313,999

G

protocadherin alpha subfamily C, 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PCDHAC2 mRNA

Ensembl chr18:28,581,225...28,846,211

G

protocadherin gamma subfamily A, 9

decreases expression
multiple interactions

chrysene results in decreased expression of PCDHGA9 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PCDHGA9 mRNA

PMID:26377693 PMID:27858113

NCBI chr18:29,564,614...29,667,865

G

Purkinje cell protein 2

increases expression

chrysene results in increased expression of PCP2 mRNA

NCBI chr12:1,681,659...1,683,899
Ensembl chr12:1,681,659...1,683,899

G

PDGFA associated protein 1

increases expression

chrysene results in increased expression of PDAP1 mRNA

NCBI chr12:9,470,652...9,480,880
Ensembl chr12:9,470,574...9,535,374

G

phosphodiesterase 4A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PDE4A mRNA

NCBI chr 8:19,690,816...19,753,538
Ensembl chr 8:19,703,290...19,751,961

G

pyruvate dehydrogenase kinase 2

increases expression

chrysene results in increased expression of PDK2 mRNA

NCBI chr10:79,972,550...79,987,074
Ensembl chr10:79,972,556...79,987,085

G

pyridoxal kinase

decreases expression

chrysene results in decreased expression of PDXK mRNA

NCBI chr20:10,210,276...10,232,314
Ensembl chr20:10,210,289...10,232,110

G

phosphatidylethanolamine binding protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PEBP1 mRNA

NCBI chr12:39,302,864...39,307,064
Ensembl chr12:39,302,840...39,307,862

G

platelet and endothelial cell adhesion molecule 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PECAM1 mRNA

NCBI chr10:91,590,521...91,652,279
Ensembl chr10:91,590,521...91,652,116

G

period circadian regulator 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PER1 mRNA

NCBI chr10:53,800,126...53,814,963
Ensembl chr10:53,805,535...53,814,431

G

period circadian regulator 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PER2 mRNA

NCBI chr 9:92,007,289...92,049,551
Ensembl chr 9:92,007,296...92,049,459

G

period circadian regulator 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PER3 mRNA

NCBI chr 5:161,460,228...161,495,404
Ensembl chr 5:161,459,533...161,495,607

G

6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PFKFB3 mRNA

NCBI chr17:66,983,629...67,064,702
Ensembl chr17:66,983,686...67,063,125

G

post-GPI attachment to proteins 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PGAP2 mRNA

NCBI chr 1:156,591,540...156,618,116
Ensembl chr 1:156,591,615...156,618,114

G

PHD finger protein 19

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PHF19 mRNA

NCBI chr 3:18,175,281...18,197,289
Ensembl chr 3:18,175,282...18,196,405

G

PHD finger protein 20-like 1

decreases expression

chrysene results in decreased expression of PHF20L1 mRNA

NCBI chr 7:98,330,580...98,396,526
Ensembl chr 7:98,330,580...98,396,526

G

PHD finger protein 21A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PHF21A mRNA

NCBI chr 3:78,158,760...78,331,903
Ensembl chr 3:78,194,549...78,331,865

G

pleckstrin homology-like domain, family A, member 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PHLDA3 mRNA

NCBI chr13:47,193,250...47,196,335
Ensembl chr13:47,193,086...47,196,335

G

PH domain and leucine rich repeat protein phosphatase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PHLPP1 mRNA

NCBI chr13:22,308,532...22,530,978
Ensembl chr13:22,308,548...22,530,977

G

phytanoyl-CoA 2-hydroxylase interacting protein

increases expression

chrysene results in increased expression of PHYHIP mRNA

NCBI chr15:45,533,974...45,545,223
Ensembl chr15:45,533,974...45,545,221

G

piezo-type mechanosensitive ion channel component 1

increases expression

chrysene results in increased expression of PIEZO1 mRNA

NCBI chr19:50,544,580...50,606,812
Ensembl chr19:50,544,582...50,606,501

G

polymeric immunoglobulin receptor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PIGR mRNA

NCBI chr13:42,298,905...42,326,877
Ensembl chr13:42,298,914...42,326,875

G

Pim-1 proto-oncogene, serine/threonine kinase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PIM1 mRNA

NCBI chr20:7,554,921...7,559,174
Ensembl chr20:7,554,921...7,559,174

G

PICALM interacting mitotic regulator

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PIMREG mRNA

NCBI chr10:56,669,603...56,674,540
Ensembl chr10:56,669,675...56,674,791

G

PIN2/TERF1 interacting, telomerase inhibitor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PINX1 mRNA

NCBI chr15:38,097,896...38,157,143
Ensembl chr15:38,097,886...38,157,140

G

phosphatidylinositol-4,5-bisphosphate 4-phosphatase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PIP4P1 mRNA

NCBI chr15:24,146,854...24,150,739
Ensembl chr15:24,146,856...24,150,702

G

cAMP-dependent protein kinase inhibitor alpha

increases expression

chrysene results in increased expression of PKIA mRNA

NCBI chr 2:94,398,869...94,473,638
Ensembl chr 2:94,398,869...94,414,282

G

cAMP-dependent protein kinase inhibitor gamma

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PKIG mRNA

NCBI chr 3:152,330,477...152,398,085
Ensembl chr 3:152,366,041...152,398,082

G

protein kinase N3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PKN3 mRNA

NCBI chr 3:13,350,082...13,363,572
Ensembl chr 3:13,335,041...13,363,567

G

placenta associated 8

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PLAC8 mRNA

NCBI chr14:9,052,601...9,074,264
Ensembl chr14:9,063,048...9,074,264

G

PLAG1 like zinc finger 2

increases expression

chrysene results in increased expression of PLAGL2 mRNA

NCBI chr 3:141,695,322...141,708,516
Ensembl chr 3:141,695,322...141,708,503

G

plasminogen activator, tissue type

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PLAT mRNA

NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223

G

phospholipase C beta 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PLCB1 mRNA

NCBI chr 3:122,059,988...122,772,896
Ensembl chr 3:122,060,031...122,772,869

G

phospholipase C, delta 1

increases expression

chrysene results in increased expression of PLCD1 mRNA

NCBI chr 8:118,795,196...118,818,186
Ensembl chr 8:118,795,201...118,818,186

G

phospholipase C, delta 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PLCD4 mRNA

NCBI chr 9:76,115,523...76,158,602
Ensembl chr 9:76,117,168...76,142,453

G

phospholipase C, eta 2

increases expression

chrysene results in increased expression of PLCH2 mRNA

NCBI chr 5:165,544,209...165,613,769
Ensembl chr 5:165,544,200...165,602,356

G

pleckstrin homology and RhoGEF domain containing G6

increases expression

chrysene results in increased expression of PLEKHG6 mRNA

NCBI chr 4:158,163,443...158,182,628
Ensembl chr 4:158,162,969...158,182,271

G

pleckstrin homology, MyTH4 and FERM domain containing H3

increases expression

chrysene results in increased expression of PLEKHH3 mRNA

NCBI chr10:86,098,461...86,106,931
Ensembl chr10:86,098,469...86,106,880

G

polo-like kinase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PLK2 mRNA

NCBI chr 2:41,969,176...41,974,945
Ensembl chr 2:41,969,176...41,974,947

G

polo-like kinase 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PLK5 mRNA

NCBI chr 7:9,346,777...9,367,923
Ensembl chr 7:9,346,777...9,355,196

G

phospholipid phosphatase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PPAP2A mRNA

NCBI chr 2:44,439,002...44,500,430
Ensembl chr 2:44,438,994...44,501,268

G

phorbol-12-myristate-13-acetate-induced protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PMAIP1 mRNA

NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429

G

peripheral myelin protein 22

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PMP22 mRNA

NCBI chr10:47,795,709...47,825,715
Ensembl chr10:47,795,709...47,825,714

G

pregnancy up-regulated nonubiquitous CaM kinase

increases expression

chrysene results in increased expression of PNCK mRNA

NCBI chr X:151,369,406...151,373,508
Ensembl chr X:151,369,410...151,373,446

G

PNMA family member 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PNMA2 mRNA

NCBI chr15:41,111,942...41,119,649
Ensembl chr15:41,112,009...41,121,427

G

DNA polymerase delta interacting protein 3

increases expression

chrysene results in increased expression of POLDIP3 mRNA

NCBI chr 7:114,274,845...114,303,278
Ensembl chr 7:114,275,085...114,303,271

G

DNA polymerase kappa

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of POLK mRNA

NCBI chr 2:27,822,228...27,882,331
Ensembl chr 2:27,822,679...27,882,313

G

proteasome maturation protein

decreases expression

chrysene results in decreased expression of POMP mRNA

NCBI chr12:7,162,098...7,174,737
Ensembl chr12:7,160,714...7,174,715

G

paraoxonase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PON2 mRNA

NCBI chr 4:33,389,702...33,425,186
Ensembl chr 4:33,389,714...33,425,248

G

POU class 2 homeobox associating factor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of POU2AF1 mRNA

NCBI chr 8:51,521,813...51,548,819
Ensembl chr 8:51,474,015...51,548,819

G

PTPRF interacting protein alpha 3

increases expression

chrysene results in increased expression of PPFIA3 mRNA

NCBI chr 1:95,817,110...95,845,950
Ensembl chr 1:95,817,110...95,845,798

G

peptidylprolyl isomerase G

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PPIG mRNA

NCBI chr 3:54,484,023...54,512,929
Ensembl chr 3:54,484,023...54,512,926

G

protein phosphatase, Mg2+/Mn2+ dependent, 1A

decreases expression

chrysene results in decreased expression of PPM1A mRNA

NCBI chr 6:91,439,094...91,486,139
Ensembl chr 6:91,438,834...91,480,697

G

prickle planar cell polarity protein 3

increases expression

chrysene results in increased expression of PRICKLE3 mRNA

NCBI chr X:14,837,647...14,849,305
Ensembl chr X:14,837,650...14,848,218

G

protein kinase AMP-activated non-catalytic subunit gamma 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PRKAG3 mRNA

NCBI chr 9:76,295,715...76,304,959
Ensembl chr 9:76,295,715...76,304,959

G

protein kinase C, epsilon

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PRKCE mRNA

NCBI chr 6:7,965,048...8,451,966
Ensembl chr 6:7,965,048...8,451,719

G

protein kinase C, iota

increases expression

chrysene results in increased expression of PRKCI mRNA

NCBI chr 2:112,321,919...112,382,305
Ensembl chr 2:112,321,929...112,382,352

G

proline and serine rich 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PROSER2 mRNA

NCBI chr17:72,151,961...72,187,524
Ensembl chr17:72,151,872...72,185,825

G

pre-mRNA processing factor 38B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PRPF38B mRNA

NCBI chr 2:196,553,224...196,562,271
Ensembl chr 2:196,553,225...196,562,250

G

pre-mRNA processing factor 4B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PRPF4B mRNA

NCBI chr17:29,985,343...30,020,285
Ensembl chr17:29,985,343...30,019,625

G

proline rich 7 (synaptic)

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PRR7 mRNA

NCBI chr17:9,164,375...9,173,669
Ensembl chr17:9,165,269...9,172,536

G

proline rich and Gla domain 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PRRG3 mRNA

NCBI chr X:149,666,498...149,689,353
Ensembl chr X:149,670,257...149,677,373

G

serine protease 12

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PRSS12 mRNA

NCBI chr 2:211,624,134...211,684,126
Ensembl chr 2:211,624,134...211,684,126

G

serine protease 23

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PRSS23 mRNA

NCBI chr 1:143,402,725...143,422,182
Ensembl chr 1:143,401,396...143,422,091

G

proteasome 26S subunit, non-ATPase 3

increases expression

chrysene results in increased expression of PSMD3 mRNA

NCBI chr10:83,643,473...83,655,620
Ensembl chr10:83,643,647...83,655,618

G

proline and serine rich coiled-coil 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PSRC1 mRNA

NCBI chr 2:196,022,361...196,026,874
Ensembl chr 2:196,022,361...196,026,874

G

polypyrimidine tract binding protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PTBP1 mRNA

NCBI chr 7:9,842,574...9,852,332
Ensembl chr 7:9,842,574...9,852,397

G

prothymosin alpha

increases expression
multiple interactions

chrysene results in increased expression of PTMA mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PTMA mRNA

PMID:26377693 PMID:27858113

NCBI chr 9:87,176,251...87,180,333
Ensembl chr 9:87,176,230...87,180,333

G

protein tyrosine phosphatase, non-receptor type 5

decreases expression

chrysene results in decreased expression of PTPN5 mRNA

NCBI chr 1:97,620,638...97,681,186
Ensembl chr 1:97,620,642...97,679,882

G

protein tyrosine phosphatase, receptor type, B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of PTPRB mRNA

NCBI chr 7:51,953,375...52,034,751
Ensembl chr 7:51,930,015...52,034,748

G

protein tyrosine phosphatase, receptor type, G

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of PTPRG mRNA

NCBI chr15:12,871,706...13,552,186
Ensembl chr15:12,871,721...13,554,094

G

protein tyrosine phosphatase, receptor type Z1

increases expression

chrysene results in increased expression of PTPRZ1 mRNA

NCBI chr 4:51,397,316...51,595,220
Ensembl chr 4:51,397,601...51,595,218

G

RAB11 family interacting protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RAB11FIP1 mRNA

NCBI chr16:64,886,902...64,917,491
Ensembl chr16:64,884,676...64,917,491

G

RAB44, member RAS oncogene family

increases expression

chrysene results in increased expression of RAB44 mRNA

NCBI chr20:7,164,576...7,198,473
Ensembl chr20:7,164,720...7,198,468

G

Rab acceptor 1

decreases expression

chrysene results in decreased expression of RABAC1 mRNA

NCBI chr 1:80,564,029...80,567,164
Ensembl chr 1:80,564,033...80,567,163

G

Rab geranylgeranyltransferase subunit beta

decreases expression

chrysene results in decreased expression of RABGGTB mRNA

NCBI chr 2:242,844,758...242,850,951
Ensembl chr 2:242,844,762...242,851,050

G

RAD51 recombinase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RAD51 mRNA

NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035

G

retinoic acid induced 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RAI2 mRNA

NCBI chr X:32,948,656...33,011,222
Ensembl chr X:32,948,656...33,011,264

G

receptor activity modifying protein 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RAMP3 mRNA

NCBI chr14:81,527,404...81,544,905
Ensembl chr14:81,527,385...81,544,902

G

RASD family, member 2

increases expression
multiple interactions

chrysene results in increased expression of RASD2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RASD2 mRNA

PMID:26377693 PMID:27858113

NCBI chr19:13,594,291...13,605,016
Ensembl chr19:13,594,291...13,605,016

G

RasGEF domain family, member 1C

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RASGEF1C mRNA

NCBI chr10:34,227,483...34,293,676
Ensembl chr10:34,227,483...34,293,675

G

RAS guanyl releasing protein 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RASGRP3 mRNA

NCBI chr 6:19,895,361...19,993,945
Ensembl chr 6:19,895,390...19,958,578

G

RAS-like family 11 member A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RASL11A mRNA

NCBI chr12:8,258,148...8,260,909
Ensembl chr12:8,258,159...8,262,576

G

Ras association domain family member 1

increases expression

chrysene results in increased expression of RASSF1 mRNA

NCBI chr 8:108,225,023...108,236,164
Ensembl chr 8:108,225,023...108,236,164

G

Ras association domain family member 8

decreases expression

chrysene results in decreased expression of RASSF8 mRNA

NCBI chr 4:178,716,110...178,798,042
Ensembl chr 4:178,719,992...178,796,690

G

RNA binding motif protein 25

increases expression

chrysene results in increased expression of RBM25 mRNA

NCBI chr 6:103,271,775...103,319,090
Ensembl chr 6:103,271,801...103,317,854

G

RNA binding motif protein 39

increases expression

chrysene results in increased expression of RBM39 mRNA

NCBI chr 3:144,662,998...144,696,222
Ensembl chr 3:144,663,001...144,696,213

G

RNA binding motif protein 6

increases expression

chrysene results in increased expression of RBM6 mRNA

NCBI chr 8:108,452,687...108,552,783
Ensembl chr 8:108,452,687...108,552,771

G

retinol binding protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RBP1 mRNA

NCBI chr 8:99,025,218...99,046,740
Ensembl chr 8:99,025,206...99,046,743

G

receptor accessory protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of REEP1 mRNA

NCBI chr 4:103,746,004...103,862,347
Ensembl chr 4:103,745,633...103,862,338

G

receptor accessory protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of REEP2 mRNA

NCBI chr18:26,438,130...26,447,165
Ensembl chr18:26,438,346...26,447,161

G

REV1, DNA directed polymerase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of REV1 mRNA

NCBI chr 9:40,278,100...40,351,764
Ensembl chr 9:40,278,101...40,351,576

G

REX4 homolog, 3'-5' exonuclease

increases expression

chrysene results in increased expression of REXO4 mRNA

NCBI chr 3:10,280,654...10,291,003
Ensembl chr 3:10,280,654...10,290,996

G

regulator of G-protein signaling 12

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RGS12 mRNA

NCBI chr14:75,715,925...75,824,012
Ensembl chr14:75,715,934...75,794,596

G

regulator of G-protein signaling 7 binding protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RGS7BP mRNA

NCBI chr 2:36,133,944...36,231,505
Ensembl chr 2:36,139,201...36,231,505

G

ras homolog family member B

decreases expression
multiple interactions

chrysene results in decreased expression of RHOB mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RHOB mRNA

PMID:26377693 PMID:27858113

NCBI chr 6:31,363,752...31,365,926
Ensembl chr 6:31,363,548...31,366,108

G

ras homolog family member C

increases expression

chrysene results in increased expression of RHOC mRNA

NCBI chr 2:192,287,065...192,293,292
Ensembl chr 2:192,287,130...192,295,306

G

ras homolog family member T2

increases expression

chrysene results in increased expression of RHOT2 mRNA

NCBI chr10:14,858,954...14,864,751
Ensembl chr10:14,858,956...14,864,751

G

reproductive homeobox 8

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RHOX8 mRNA

NCBI chr X:116,584,742...116,588,365
Ensembl chr X:116,584,582...116,588,365

G

ripply transcriptional repressor 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RIPPLY3 mRNA

NCBI chr11:33,648,471...33,656,587
Ensembl chr11:33,648,486...33,656,584

G

ribonuclease A family member 10

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RNASE10 mRNA

NCBI chr15:24,226,687...24,229,149
Ensembl chr15:24,226,691...24,228,561

G

ribonuclease H2, subunit B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RNASEH2B mRNA

NCBI chr15:36,541,200...36,592,016
Ensembl chr15:36,541,218...36,584,118

G

ring finger protein 144A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RNF144A mRNA

NCBI chr 6:42,899,767...43,019,769
Ensembl chr 6:42,903,174...43,020,012

G

ring finger protein 169

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RNF169 mRNA

NCBI chr 1:154,250,462...154,311,867
Ensembl chr 1:154,254,473...154,311,653

G

ring finger protein 20

increases expression

chrysene results in increased expression of RNF20 mRNA

NCBI chr 5:63,976,063...64,001,754
Ensembl chr 5:63,976,045...64,001,754

G

ring finger protein 43

increases expression

chrysene results in increased expression of RNF43 mRNA

NCBI chr10:72,461,508...72,537,301
Ensembl chr10:72,464,348...72,536,977

G

roundabout guidance receptor 1

decreases expression

chrysene results in decreased expression of ROBO1 mRNA

NCBI chr11:10,580,863...11,621,675
Ensembl chr11:10,580,908...11,620,203

G

Rho-associated coiled-coil containing protein kinase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ROCK2 mRNA

NCBI chr 6:39,679,116...39,774,033
Ensembl chr 6:39,679,082...39,774,031

G

RAR-related orphan receptor C

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RORC mRNA

NCBI chr 2:182,009,707...182,034,910
Ensembl chr 2:182,009,286...182,034,907

G

RNA polymerase II associated protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RPAP2 mRNA

NCBI chr14:2,109,044...2,187,343
Ensembl chr14:2,109,053...2,187,350

G

ribosomal protein S27-like

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RPS27L mRNA

NCBI chr 8:67,562,483...67,567,418
Ensembl chr 8:67,562,483...67,567,418

G

ribonucleotide reductase catalytic subunit M1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RRM1 mRNA

NCBI chr 1:156,823,960...156,848,262
Ensembl chr 1:156,823,960...156,848,261

G

ribonucleotide reductase regulatory subunit M2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of RRM2 mRNA

NCBI chr 6:41,339,858...41,346,774
Ensembl chr 6:41,340,557...41,346,773

G

ribosomal RNA processing 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RRP1 mRNA

NCBI chr20:10,260,892...10,272,141
Ensembl chr20:10,260,870...10,272,144

G

retinoschisin 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RS1 mRNA

NCBI chr X:33,962,440...33,992,203
Ensembl chr X:33,963,657...33,992,115

G

arginine and serine rich protein 1

increases expression

chrysene results in increased expression of RSRP1 mRNA

NCBI chr 5:147,147,774...147,151,523
Ensembl chr 5:147,147,784...147,151,523

G

RT1 class II, locus DOa

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of H2-OA mRNA

NCBI chr20:4,753,587...4,756,590
Ensembl chr20:4,753,598...4,756,577

G

RT1 class II, locus DOb

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of H2-OB mRNA

NCBI chr20:4,619,418...4,625,627
Ensembl chr20:4,619,816...4,625,667

G

reticulon 3

decreases expression

chrysene results in decreased expression of RTN3 mRNA

NCBI chr 1:204,612,675...204,669,212
Ensembl chr 1:204,612,675...204,669,275

G

receptor (chemosensory) transporter protein 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RTP3 mRNA

NCBI chr 8:110,970,154...110,975,000
Ensembl chr 8:110,970,160...110,974,699

G

receptor (chemosensory) transporter protein 4

decreases expression

chrysene results in decreased expression of RTP4 mRNA

NCBI chr11:77,237,341...77,249,194
Ensembl chr11:77,238,216...77,335,437

G

RUN and FYVE domain containing 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of RUFY2 mRNA

NCBI chr20:25,626,958...25,658,157
Ensembl chr20:25,621,999...25,658,186

G

ryanodine receptor 1

increases expression

chrysene results in increased expression of RYR1 mRNA

NCBI chr 1:84,292,578...84,423,824
Ensembl chr 1:84,292,578...84,423,812

G

S100 calcium binding protein A14

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of S100A14 mRNA

NCBI chr 2:176,008,395...176,010,423
Ensembl chr 2:176,008,395...176,010,423

G

S100 calcium binding protein A6

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of S100A6 mRNA

NCBI chr 2:176,100,619...176,102,181
Ensembl chr 2:176,100,899...176,102,180

G

sphingosine-1-phosphate receptor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of S1PR1 mRNA

NCBI chr 2:203,624,752...203,629,110
Ensembl chr 2:203,621,587...203,629,681

G

SAC3 domain containing 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SAC3D1 mRNA

NCBI chr 1:203,414,184...203,416,563
Ensembl chr 1:203,414,187...203,416,604

G

scaffold attachment factor B2

increases expression

chrysene results in increased expression of SAFB2 mRNA

NCBI chr 9:1,395,852...1,417,010
Ensembl chr 9:1,387,107...1,417,038

G

suprabasin

increases expression

chrysene results in increased expression of SBSN mRNA

NCBI chr 1:85,978,970...86,006,034
Ensembl chr 1:86,001,567...86,006,034

G

stearoyl-CoA desaturase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SCD1 mRNA

NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562

G

sodium voltage-gated channel beta subunit 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SCN3B mRNA

NCBI chr 8:40,630,372...40,652,869
Ensembl chr 8:40,630,455...40,652,868

G

SCY1 like pseudokinase 1

increases expression

chrysene results in increased expression of SCYL1 mRNA

NCBI chr 1:203,045,776...203,059,550
Ensembl chr 1:203,045,741...203,059,533

G

stromal cell derived factor 4

decreases expression
multiple interactions

chrysene results in decreased expression of SDF4 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SDF4 mRNA

PMID:26377693 PMID:27858113

NCBI chr 5:166,586,581...166,606,661
Ensembl chr 5:166,586,390...166,604,521

G

SEC61 translocon subunit beta

decreases expression

chrysene results in decreased expression of SEC61B mRNA

NCBI chr 5:61,773,594...61,781,804
Ensembl chr 5:61,773,594...61,781,804

G

selenoprotein S

decreases expression

chrysene results in decreased expression of SELENOS mRNA

NCBI chr 1:119,659,779...119,669,546
Ensembl chr 1:119,659,751...119,669,833

G

selectin L

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SELL mRNA

NCBI chr13:76,416,969...76,436,444
Ensembl chr13:76,416,915...76,436,456

G

semaphorin 3C

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SEMA3C mRNA

NCBI chr 4:17,583,212...17,747,234
Ensembl chr 4:17,583,212...17,746,534

G

septin 11

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SEPTIN11 mRNA

NCBI chr14:14,844,759...14,990,856
Ensembl chr14:14,844,580...14,990,853

G

septin 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SEPTIN3 mRNA

NCBI chr 7:113,783,217...113,811,089
Ensembl chr 7:113,783,095...113,811,087

G

stress-associated endoplasmic reticulum protein family member 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SERP2 mRNA

NCBI chr15:51,879,882...51,903,958
Ensembl chr15:51,879,877...51,904,785

G

serpin family B member 10

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SERPINB10 mRNA

NCBI chr13:23,553,348...23,571,182
Ensembl chr13:23,553,430...23,571,182

G

serpin family B member 1A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SERPINB1A mRNA

NCBI chr17:31,590,695...31,599,102
Ensembl chr17:31,590,677...31,599,102

G

serpin family B member 5

increases expression

chrysene results in increased expression of SERPINB5 mRNA

NCBI chr13:22,985,557...23,005,756
Ensembl chr13:22,985,557...23,005,756

G

serpin family E member 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SERPINE1 mRNA

NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657

G

SERTA domain containing 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SERTAD2 mRNA

NCBI chr14:94,733,637...94,838,200
Ensembl chr14:94,733,579...94,838,313

G

sestrin 2

decreases expression
multiple interactions

chrysene results in decreased expression of SESN2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SESN2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260

G

SET domain containing 1B, histone lysine methyltransferase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SETD1B mRNA

NCBI chr12:33,395,963...33,421,671
Ensembl chr12:33,396,120...33,426,934

G

SET domain containing 6, protein lysine methyltransferase

increases expression

chrysene results in increased expression of SETD6 mRNA

NCBI chr19:9,343,309...9,350,477
Ensembl chr19:9,347,458...9,350,453

G

SFI1 centrin binding protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SFI1 mRNA

NCBI chr14:77,990,965...78,048,352
Ensembl chr14:77,990,965...78,048,255

G

SWI5-dependent homologous recombination repair protein 1

increases expression

chrysene results in increased expression of SFR1 mRNA

NCBI chr 1:246,619,235...246,623,250
Ensembl chr 1:246,597,044...246,623,250

G

secreted frizzled-related protein 2

increases expression

chrysene results in increased expression of SFRP2 mRNA

NCBI chr 2:169,089,517...169,097,064
Ensembl chr 2:169,089,517...169,097,063

G

sideroflexin 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SFXN2 mRNA

NCBI chr 1:245,447,014...245,459,312
Ensembl chr 1:245,447,015...245,468,411
Ensembl chr 1:245,447,015...245,468,411

G

sphingomyelin synthase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SGMS1 mRNA

NCBI chr 1:229,996,673...230,259,591
Ensembl chr 1:229,998,119...230,259,603

G

SH3 domain binding glutamate-rich protein

increases expression

chrysene results in increased expression of SH3BGR mRNA

NCBI chr11:35,503,663...35,527,853
Ensembl chr11:35,503,725...35,527,853

G

SH3-domain binding protein 1

increases expression

chrysene results in increased expression of SH3BP1 mRNA

NCBI chr 7:110,457,626...110,470,201
Ensembl chr 7:110,457,710...110,470,201

G

SH3 domain containing 19

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SH3D19 mRNA

NCBI chr 2:171,356,244...171,516,042
Ensembl chr 2:171,356,251...171,515,561

G

SH3 and PX domains 2A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SH3PXD2A mRNA

NCBI chr 1:246,153,660...246,359,806
Ensembl chr 1:246,160,502...246,360,166

G

SHC adaptor protein 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SHC4 mRNA

NCBI chr 3:112,880,598...112,974,216
Ensembl chr 3:112,880,600...112,974,366

G

shisa family member 2

increases expression

chrysene results in increased expression of SHISA2 mRNA

NCBI chr15:33,806,715...33,811,013
Ensembl chr15:33,805,958...33,811,013

G

solute carrier family 19 member 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SLC19A2 mRNA

NCBI chr13:76,601,975...76,616,175
Ensembl chr13:76,601,900...76,616,172

G

solute carrier family 25 member 33

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SLC25A33 mRNA

NCBI chr 5:160,195,040...160,219,961
Ensembl chr 5:160,195,042...160,219,961

G

solute carrier family 26, member 10

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SLC26A10 mRNA

NCBI chr 7:62,995,165...63,005,099
Ensembl chr 7:62,995,381...63,004,087

G

solute carrier family 26 member 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SLC26A4 mRNA

NCBI chr 6:48,107,575...48,153,762
Ensembl chr 6:48,107,588...48,145,703

G

solute carrier family 2 member 6

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SLC2A6 mRNA

NCBI chr 3:10,348,395...10,355,208
Ensembl chr 3:10,348,395...10,355,208

G

solute carrier family 2 member 9

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SLC2A9 mRNA

NCBI chr14:72,328,334...72,461,981
Ensembl chr14:72,328,320...72,461,981

G

solute carrier family 30 member 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SLC30A1 mRNA

NCBI chr13:103,491,037...103,494,910
Ensembl chr13:103,491,037...103,494,910

G

solute carrier family 35, member G2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SLC35G2 mRNA

NCBI chr 8:101,085,579...101,113,339
Ensembl chr 8:101,085,545...101,113,349

G

solute carrier family 3 member 2

increases expression

chrysene results in increased expression of SLC3A2 mRNA

NCBI chr 1:205,604,468...205,618,931
Ensembl chr 1:205,604,468...205,618,931

G

solute carrier family 45, member 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SLC45A4 mRNA

NCBI chr 7:105,478,886...105,550,160
Ensembl chr 7:105,481,792...105,550,170

G

solute carrier family 46, member 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SLC46A3 mRNA

NCBI chr12:7,140,610...7,157,093
Ensembl chr12:7,140,668...7,157,092

G

solute carrier family 5 member 12

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SLC5A12 mRNA

NCBI chr 3:97,179,326...97,228,405
Ensembl chr 3:97,179,326...97,228,405

G

solute carrier family 5 member 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SLC5A3 mRNA

NCBI chr11:31,313,847...31,316,293
Ensembl chr11:31,295,476...31,318,883

G

solute carrier family 66 member 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SLC66A3 mRNA

NCBI chr 6:39,774,801...39,786,554
Ensembl chr 6:39,774,808...39,786,303

G

solute carrier family 7 member 5

increases expression

chrysene results in increased expression of SLC7A5 mRNA

NCBI chr19:49,935,220...49,963,823
Ensembl chr19:49,935,220...49,963,823

G

solute carrier family 8 member A1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SLC8A1 mRNA

NCBI chr 6:13,194,609...13,547,369
Ensembl chr 6:13,194,662...13,535,628

G

sarcolemma associated protein

increases expression

chrysene results in increased expression of SLMAP mRNA

NCBI chr16:1,667,205...1,785,200
Ensembl chr16:1,667,208...1,785,149

G

structural maintenance of chromosomes 1A

increases expression

chrysene results in increased expression of SMC1A mRNA

NCBI chr X:21,103,323...21,148,053
Ensembl chr X:21,103,282...21,148,056

G

SPARC related modular calcium binding 2

increases expression

chrysene results in increased expression of SMOC2 mRNA

NCBI chr 1:55,262,472...55,391,804
Ensembl chr 1:55,262,530...55,391,693

G

sphingomyelin phosphodiesterase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SMPD2 mRNA

NCBI chr20:44,986,229...44,989,343
Ensembl chr20:44,986,231...44,989,441

G

sphingomyelin phosphodiesterase 3

increases expression

chrysene results in increased expression of SMPD3 mRNA

NCBI chr19:34,162,337...34,245,786
Ensembl chr19:34,162,341...34,245,749

G

smoothelin-like 1

increases expression

chrysene results in increased expression of SMTNL1 mRNA

NCBI chr 3:69,889,010...69,901,096
Ensembl chr 3:69,889,010...69,901,079

G

snail family transcriptional repressor 2

increases expression

chrysene results in increased expression of SNAI2 mRNA

NCBI chr11:86,182,788...86,186,203
Ensembl chr11:86,181,909...86,186,200

G

synaptosome associated protein 23

decreases expression
multiple interactions

chrysene results in decreased expression of SNAP23 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SNAP23 mRNA

PMID:26377693 PMID:27858113

NCBI chr 3:107,514,088...107,546,177
Ensembl chr 3:107,514,131...107,544,320

G

synaptosome associated protein 47

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SNAP47 mRNA

NCBI chr10:44,192,886...44,234,435
Ensembl chr10:44,191,218...44,234,424

G

small nucleolar RNA, C/D box 123

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SNORD123 mRNA

NCBI chr 2:83,306,918...83,306,987
Ensembl chr 2:83,306,918...83,306,987

G

small nuclear ribonucleoprotein U1 subunit 70

increases expression

chrysene results in increased expression of SNRNP70 mRNA

NCBI chr 1:95,856,038...95,876,434
Ensembl chr 1:95,856,036...95,876,392

G

syntrophin, beta 1

decreases expression
multiple interactions

chrysene results in decreased expression of SNTB1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SNTB1 mRNA

PMID:26377693 PMID:27858113

NCBI chr 7:87,060,926...87,329,315
Ensembl chr 7:87,060,926...87,329,315

G

sorbin and SH3 domain containing 1

increases expression

chrysene results in increased expression of SORBS1 mRNA

NCBI chr 1:239,107,882...239,330,276
Ensembl chr 1:239,108,777...239,330,169

G

sorbitol dehydrogenase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SORD mRNA

NCBI chr 3:109,184,697...109,216,133
Ensembl chr 3:109,184,676...109,216,133

G

SRY-box transcription factor 17

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SOX17 mRNA

NCBI chr 5:15,016,660...15,022,228
Ensembl chr 5:15,016,731...15,022,228

G

SRY-box transcription factor 2

increases expression

chrysene results in increased expression of SOX2 mRNA

NCBI chr 2:117,536,929...117,539,340
Ensembl chr 2:117,536,929...117,539,338

G

SRY-box transcription factor 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SOX4 mRNA

NCBI chr17:35,667,809...35,672,515
Ensembl chr17:35,667,537...35,673,665

G

SPARC like 1

increases expression

chrysene results in increased expression of SPARCL1 mRNA

NCBI chr14:5,632,816...5,663,866
Ensembl chr14:5,632,569...5,663,865

G

SPC25 component of NDC80 kinetochore complex

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SPC25 mRNA

NCBI chr 3:53,930,013...53,988,940
Ensembl chr 3:53,975,704...53,988,959

G

signal peptidase complex subunit 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SPCS2 mRNA

NCBI chr 1:154,163,724...154,183,152
Ensembl chr 1:154,163,724...154,183,186

G

Spi-B transcription factor

increases expression

chrysene results in increased expression of SPIB mRNA

NCBI chr 1:95,018,939...95,024,804
Ensembl chr 1:95,018,947...95,024,780

G

spindlin 1

decreases expression
multiple interactions

chrysene results in decreased expression of SPIN1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SPIN1 mRNA

PMID:26377693 PMID:27858113

NCBI chr17:14,055,685...14,105,366
Ensembl chr17:14,055,689...14,105,411

G

serine peptidase inhibitor, Kazal type 1

increases expression

chrysene results in increased expression of SPINK1 mRNA

NCBI chr18:35,870,723...35,882,693
Ensembl chr18:35,824,550...35,882,642

G

spondin 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SPON2 mRNA

NCBI chr14:77,505,695...77,518,001
Ensembl chr14:77,511,901...77,517,996

G

secreted phosphoprotein 1

decreases expression

chrysene results in decreased expression of SPP1 mRNA

NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162

G

spectrin, beta, non-erythrocytic 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SPTBN1 mRNA

NCBI chr14:103,841,713...104,016,900
Ensembl chr14:103,842,684...104,008,507

G

SRC kinase signaling inhibitor 1

increases expression

chrysene results in increased expression of SRCIN1 mRNA

NCBI chr10:82,502,911...82,569,882
Ensembl chr10:82,504,393...82,571,040

G

serglycin

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SRGN mRNA

NCBI chr20:30,442,810...30,479,549
Ensembl chr20:30,442,813...30,457,406

G

signal recognition particle 9

decreases expression

chrysene results in decreased expression of SRP9 mRNA

NCBI chr13:93,832,580...93,840,720
Ensembl chr13:93,832,580...93,840,720

G

SRSF protein kinase 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SRPK3 mRNA

NCBI chr X:151,510,452...151,515,208
Ensembl chr X:151,510,539...151,515,198

G

serine/arginine repetitive matrix 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SRRM2 mRNA

NCBI chr10:12,815,471...12,848,750
Ensembl chr10:12,815,471...12,848,751

G

serine and arginine rich splicing factor 5

increases expression

chrysene results in increased expression of SRSF5 mRNA

NCBI chr 6:100,605,165...100,610,192
Ensembl chr 6:100,605,456...100,610,177

G

small RNA binding exonuclease protection factor La

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SSB mRNA

NCBI chr 3:54,616,616...54,626,203
Ensembl chr 3:54,616,619...54,626,203

G

slingshot protein phosphatase 3

increases expression

chrysene results in increased expression of SSH3 mRNA

NCBI chr 1:201,557,167...201,565,577
Ensembl chr 1:201,557,169...201,564,753

G

sarcospan

increases expression
multiple interactions

chrysene results in increased expression of SSPN mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SSPN mRNA

PMID:26377693 PMID:27858113

NCBI chr 4:178,890,030...178,946,267
Ensembl chr 4:178,897,147...178,931,554

G

signal sequence receptor subunit 2

decreases expression

chrysene results in decreased expression of SSR2 mRNA

NCBI chr 2:174,048,291...174,057,043
Ensembl chr 2:174,048,460...174,057,042

G

signal sequence receptor subunit 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SSR3 mRNA

NCBI chr 2:149,605,005...149,625,069
Ensembl chr 2:149,605,005...149,625,132

G

ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ST6GALNAC1 mRNA

NCBI chr10:101,972,656...101,983,053
Ensembl chr10:101,972,668...101,983,053

G

ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ST8SIA4 mRNA

NCBI chr 9:95,990,131...96,084,661
Ensembl chr 9:95,993,503...96,084,653

G

staufen double-stranded RNA binding protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of STAU2 mRNA

NCBI chr 5:2,840,741...3,084,935
Ensembl chr 5:2,840,765...3,084,929

G

starch binding domain 1

increases expression

chrysene results in increased expression of STBD1 mRNA

NCBI chr14:15,470,452...15,473,857
Ensembl chr14:15,469,582...15,477,443

G

sulfatase 1

increases expression

chrysene results in increased expression of SULF1 mRNA

NCBI chr 5:6,362,894...6,526,174
Ensembl chr 5:6,362,911...6,525,584

G

small ubiquitin-like modifier 2

decreases expression

chrysene results in decreased expression of SUMO2 mRNA

NCBI chr10:100,771,941...100,784,503
Ensembl chr10:100,686,797...100,784,513

G

spectrin repeat containing nuclear envelope protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SYNE2 mRNA

NCBI chr 6:94,537,088...94,848,085
Ensembl chr 6:94,537,088...94,848,064

G

Sys1 golgi trafficking protein

decreases expression

chrysene results in decreased expression of SYS1 mRNA

NCBI chr 3:153,191,061...153,195,463
Ensembl chr 3:153,191,090...153,220,651

G

synaptotagmin 10

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SYT10 mRNA

NCBI chr 7:120,857,698...120,920,863
Ensembl chr 7:120,862,972...120,920,863

G

synaptotagmin 15

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SYT15 mRNA

NCBI chr16:9,532,478...9,543,288
Ensembl chr16:9,532,478...9,543,281

G

TGF-beta activated kinase 1/MAP3K7 binding protein 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TAB2 mRNA

NCBI chr 1:2,375,026...2,425,115
Ensembl chr 1:2,375,490...2,424,756

G

transforming, acidic coiled-coil containing protein 2

increases expression

chrysene results in increased expression of TACC2 mRNA

NCBI chr 1:185,139,223...185,327,881
Ensembl chr 1:185,116,111...185,327,881

G

transcriptional adaptor 2A

increases expression

chrysene results in increased expression of TADA2A mRNA

NCBI chr10:68,966,502...69,014,149
Ensembl chr10:68,966,502...69,014,105

G

TATA-box binding protein associated factor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TAF1 mRNA

NCBI chr X:66,640,915...66,716,543
Ensembl chr X:66,640,982...66,716,543

G

transporter 1, ATP binding cassette subfamily B member

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TAP1 mRNA

NCBI chr20:4,656,262...4,666,634
Ensembl chr20:4,656,263...4,666,901

G

TAR DNA binding protein

increases expression

chrysene results in increased expression of TARDBP mRNA

NCBI chr 5:159,050,518...159,062,218
Ensembl chr 5:159,051,799...159,062,055

G

T-box transcription factor 21

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TBX21 mRNA

NCBI chr10:82,082,322...82,098,831
Ensembl chr10:82,082,322...82,098,831

G

transcription elongation factor A3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TCEA3 mRNA

NCBI chr 5:148,476,941...148,509,452
Ensembl chr 5:148,476,941...148,509,448

G

transcription factor 19

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TCF19 mRNA

NCBI chr20:3,218,756...3,222,861
Ensembl chr20:3,218,693...3,223,271

G

transcription factor 7 like 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TCF7L2 mRNA

NCBI chr 1:254,785,956...254,978,967
Ensembl chr 1:254,786,091...254,978,967

G

treacle ribosome biogenesis factor 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TCOF1 mRNA

NCBI chr18:54,267,015...54,300,324
Ensembl chr18:54,267,026...54,300,324

G

tudor domain containing 3

increases expression

chrysene results in increased expression of TDRD3 mRNA

NCBI chr15:63,340,531...63,497,208
Ensembl chr15:63,341,235...63,476,110

G

testis development related protein

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TDRP mRNA

NCBI chr16:75,624,047...75,652,635
Ensembl chr16:75,624,907...75,652,420

G

tec protein tyrosine kinase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TEC mRNA

NCBI chr14:35,352,551...35,461,585
Ensembl chr14:35,352,829...35,461,557

G

tectonin beta-propeller repeat containing 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TECPR1 mRNA

NCBI chr12:10,391,587...10,420,462
Ensembl chr12:10,391,696...10,419,611

G

transmembrane epididymal family member 3

increases expression

chrysene results in increased expression of TEDDM3 mRNA

NCBI chr11:79,988,984...79,990,143
Ensembl chr11:79,989,077...79,989,961

G

TEF transcription factor, PAR bZIP family member

increases expression
multiple interactions

chrysene results in increased expression of TEF mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TEF mRNA

PMID:26377693 PMID:27858113

NCBI chr 7:113,317,191...113,341,783
Ensembl chr 7:113,317,283...113,341,783

G

teneurin transmembrane protein 2

increases expression

chrysene results in increased expression of TENM2 mRNA

NCBI chr10:20,480,662...21,706,415
Ensembl chr10:20,481,854...21,705,597

G

teneurin transmembrane protein 4

increases expression

chrysene results in increased expression of TENM4 mRNA

NCBI chr 1:149,895,097...151,263,315
Ensembl chr 1:150,780,381...151,259,144

G

TEPSIN, adaptor related protein complex 4 accessory protein

increases expression

chrysene results in increased expression of TEPSIN mRNA

NCBI chr10:105,373,939...105,381,310
Ensembl chr10:105,373,941...105,382,266

G

testis expressed 11

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TEX11 mRNA

NCBI chr X:65,932,904...66,196,525
Ensembl chr X:65,932,988...66,196,187

G

transcription factor CP2-like 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TFCP2L1 mRNA

NCBI chr13:29,733,813...29,793,870
Ensembl chr13:29,733,840...29,793,870

G

thrombospondin 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of THBS1 mRNA

NCBI chr 3:105,056,293...105,071,445
Ensembl chr 3:105,056,292...105,071,440

G

thyroid hormone receptor associated protein 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of THRAP3 mRNA

NCBI chr 5:138,445,284...138,487,544
Ensembl chr 5:138,445,295...138,487,477

G

thrombospondin type 1 domain containing 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of THSD4 mRNA

NCBI chr 8:60,384,636...60,984,419
Ensembl chr 8:60,386,875...61,024,995

G

thrombospondin type 1 domain containing 7A

decreases expression
multiple interactions

chrysene results in decreased expression of THSD7A mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of THSD7A mRNA

PMID:26377693 PMID:27858113

NCBI chr 4:40,461,124...40,899,345
Ensembl chr 4:40,460,814...40,899,583

G

thymocyte nuclear protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of THYN1 mRNA

NCBI chr 8:25,406,563...25,415,445
Ensembl chr 8:25,406,500...25,415,445

G

TIMP metallopeptidase inhibitor 1

increases expression

chrysene results in increased expression of TIMP1 mRNA

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

TLC domain containing 3B

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TLCD3B mRNA

NCBI chr 1:181,421,104...181,439,744
Ensembl chr 1:181,422,830...181,439,743

G

talin 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TLN1 mRNA

NCBI chr 5:57,787,670...57,817,900
Ensembl chr 5:57,787,943...57,817,900

G

TM2 domain containing 2

decreases expression

chrysene results in decreased expression of TM2D2 mRNA

NCBI chr16:67,016,683...67,022,206
Ensembl chr16:67,012,675...67,022,226

G

transmembrane p24 trafficking protein 9

decreases expression

chrysene results in decreased expression of TMED9 mRNA

NCBI chr17:9,029,646...9,034,160
Ensembl chr17:9,029,646...9,034,176

G

transmembrane protein with EGF-like and two follistatin-like domains 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TMEFF2 mRNA

NCBI chr 9:50,445,947...50,733,473
Ensembl chr 9:50,436,079...50,733,475

G

transmembrane protein 171

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TMEM171 mRNA

NCBI chr 2:30,035,278...30,045,996
Ensembl chr 2:30,035,278...30,045,049

G

transmembrane protein 219

decreases expression

chrysene results in decreased expression of TMEM219 mRNA

NCBI chr 1:181,496,195...181,509,259
Ensembl chr 1:181,496,192...181,534,472

G

transmembrane protein 242

decreases expression

chrysene results in decreased expression of TMEM242 mRNA

NCBI chr 1:45,992,713...46,019,684
Ensembl chr 1:45,992,713...46,019,626

G

transmembrane protein 245

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TMEM245 mRNA

NCBI chr 5:71,570,952...71,647,915
Ensembl chr 5:71,514,858...71,647,763

G

transmembrane protein 258

decreases expression

chrysene results in decreased expression of TMEM258 mRNA

NCBI chr 1:206,849,723...206,853,623

G

transmembrane protein 37

decreases expression

chrysene results in decreased expression of TMEM37 mRNA

NCBI chr13:31,184,322...31,191,477
Ensembl chr13:31,171,355...31,191,077

G

transmembrane protein 42

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TMEM42 mRNA

NCBI chr 8:122,674,793...122,677,290
Ensembl chr 8:122,674,070...122,677,276

G

transmembrane protein 91

increases expression

chrysene results in increased expression of TMEM91 mRNA

NCBI chr 1:81,179,483...81,187,005
Ensembl chr 1:81,179,156...81,185,164

G

tenascin C

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TNC mRNA

NCBI chr 5:77,375,851...77,460,712
Ensembl chr 5:77,375,851...77,460,624

G

tumor necrosis factor

increases expression

chrysene results in increased expression of TNF mRNA

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF superfamily member 10

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TNFSF10 mRNA

NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135

G

TNFAIP3 interacting protein 1

increases expression

chrysene results in increased expression of TNIP1 mRNA

NCBI chr10:39,037,048...39,084,328
Ensembl chr10:39,037,058...39,077,625

G

troponin C2, fast skeletal type

increases expression

chrysene results in increased expression of TNNC2 mRNA

NCBI chr 3:153,513,272...153,516,033
Ensembl chr 3:153,513,271...153,516,029

G

troponin T3, fast skeletal type

increases expression

chrysene results in increased expression of TNNT3 mRNA

NCBI chr 1:197,652,535...197,669,736
Ensembl chr 1:197,652,431...197,669,535

G

transportin 3

increases expression

chrysene results in increased expression of TNPO3 mRNA

NCBI chr 4:58,142,954...58,220,365
Ensembl chr 4:58,143,001...58,220,433

G

tenascin XB

increases expression

chrysene results in increased expression of TNXB mRNA

G

TOX high mobility group box family member 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TOX4 mRNA

NCBI chr15:24,989,246...25,002,833
Ensembl chr15:24,988,853...25,002,833

G

tumor protein p53

multiple interactions
increases expression

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TRP53 mRNA; chrysene promotes the reaction [Benzo(a)pyrene results in increased expression of TRP53 protein]
chrysene results in increased expression of TRP53 protein

PMID:22120587 PMID:27858113

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

tumor protein p53 inducible nuclear protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TRP53INP1 mRNA

NCBI chr 5:24,253,986...24,272,250
Ensembl chr 5:24,260,568...24,267,968

G

thiamin pyrophosphokinase 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TPK1 mRNA

NCBI chr 4:72,170,134...72,557,707
Ensembl chr 4:72,170,134...72,557,694

G

tryptase beta 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TPSB2 mRNA

NCBI chr10:14,381,779...14,383,571
Ensembl chr10:14,382,013...14,383,569

G

TRAF3 interacting protein 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TRAF3IP3 mRNA

NCBI chr13:104,694,802...104,719,655
Ensembl chr13:104,694,805...104,719,673

G

tribbles pseudokinase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TRIB2 mRNA

NCBI chr 6:38,545,971...38,570,349
Ensembl chr 6:38,545,975...38,569,370

G

tripartite motif-containing 35

decreases expression
multiple interactions

chrysene results in decreased expression of TRIM35 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TRIM35 mRNA

PMID:26377693 PMID:27858113

NCBI chr15:40,493,697...40,510,246
Ensembl chr15:40,493,755...40,510,240

G

transient receptor potential cation channel, subfamily V, member 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TRPV4 mRNA

NCBI chr12:41,938,533...41,977,517
Ensembl chr12:41,938,560...41,977,517

G

TruB pseudouridine synthase family member 2

increases expression

chrysene results in increased expression of TRUB2 mRNA

NCBI chr 3:13,049,220...13,059,836
Ensembl chr 3:13,033,745...13,059,930

G

TSC22 domain family, member 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TSC22D1 mRNA

NCBI chr15:51,750,489...51,850,958
Ensembl chr15:51,749,510...51,850,958

G

tetraspanin 17

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TSPAN17 mRNA

NCBI chr17:9,819,212...9,826,851
Ensembl chr17:9,819,202...9,826,834

G

tetraspanin 18

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TSPAN18 mRNA

NCBI chr 3:79,160,060...79,299,907
Ensembl chr 3:79,161,662...79,299,852

G

tetraspanin 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TSPAN4 mRNA

NCBI chr 1:196,571,307...196,593,842
Ensembl chr 1:196,572,228...196,617,448

G

tetratricopeptide repeat domain 7A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TTC7 mRNA

NCBI chr 6:7,159,285...7,261,826
Ensembl chr 6:7,159,061...7,261,892

G

tubulin tyrosine ligase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TTL mRNA

NCBI chr 3:116,298,813...116,328,538
Ensembl chr 3:116,298,797...116,328,538

G

tubulin tyrosine ligase like 7

increases expression

chrysene results in increased expression of TTLL7 mRNA

NCBI chr 2:235,765,786...235,889,047
Ensembl chr 2:235,765,835...235,885,047

G

taurine up-regulated 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TUG1 mRNA

NCBI chr14:78,519,894...78,526,927
Ensembl chr14:78,522,506...78,526,927

G

TUB like protein 4

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of TULP4 mRNA

NCBI chr 1:46,682,416...46,813,167
Ensembl chr 1:46,682,863...46,809,688

G

tumor suppressor candidate 3

decreases expression

chrysene results in decreased expression of TUSC3 mRNA

NCBI chr16:53,196,195...53,345,241
Ensembl chr16:53,196,195...53,344,781

G

taxilin alpha

decreases expression
multiple interactions

chrysene results in decreased expression of TXLNA mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of TXLNA mRNA

PMID:26377693 PMID:27858113

NCBI chr 5:141,969,337...141,985,054
Ensembl chr 5:141,969,346...141,984,583

G

uveal autoantigen with coiled-coil domains and ankyrin repeats

increases expression

chrysene results in increased expression of UACA mRNA

NCBI chr 8:61,259,415...61,347,789
Ensembl chr 8:61,259,477...61,347,789

G

ubiquitin-conjugating enzyme E2B

decreases expression

chrysene results in decreased expression of UBE2B mRNA

NCBI chr10:36,248,434...36,263,379
Ensembl chr10:36,248,438...36,264,665

G

ubiquitin protein ligase E3 component n-recognin 5

increases expression

chrysene results in increased expression of UBR5 mRNA

NCBI chr 7:69,115,216...69,224,843
Ensembl chr 7:69,116,761...69,224,903

G

uncoupling protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of UCP1 mRNA

NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852

G

UDP glucuronosyltransferase family 1 member A6

increases expression

chrysene results in increased expression of UGT1A6 mRNA

NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

unc-45 myosin chaperone A

increases expression

chrysene results in increased expression of UNC45A mRNA

NCBI chr 1:134,281,930...134,296,661
Ensembl chr 1:134,281,933...134,301,586

G

uroplakin 1A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of UPK1A mRNA

NCBI chr 1:85,859,672...85,870,147
Ensembl chr 1:85,859,671...85,870,354

G

uroplakin 3A

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of UPK3A mRNA

NCBI chr 7:116,128,981...116,139,950
Ensembl chr 7:116,134,874...116,139,948

G

ubiquinol-cytochrome c reductase, complex III subunit VII

decreases expression

chrysene results in decreased expression of UQCRQ mRNA

NCBI chr10:37,585,864...37,589,328
Ensembl chr10:37,586,888...37,589,169

G

ubiquitin specific peptidase 2

increases expression
multiple interactions

chrysene results in increased expression of USP2 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of USP2 mRNA

PMID:26377693 PMID:27858113

NCBI chr 8:44,411,457...44,439,668
Ensembl chr 8:44,411,607...44,438,331

G

UTP14A small subunit processome component

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of UTP14A mRNA

NCBI chr X:127,439,282...127,464,634
Ensembl chr X:127,439,268...127,464,633

G

utrophin

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of UTRN mRNA

NCBI chr 1:6,720,854...7,224,313
Ensembl chr 1:6,722,594...7,224,313

G

vasohibin 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of VASH1 mRNA

NCBI chr 6:106,330,374...106,345,740
Ensembl chr 6:106,329,123...106,345,726

G

vascular cell adhesion molecule 1

decreases expression

chrysene results in decreased expression of VCAM1 mRNA

NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958

G

VPS16 core subunit of CORVET and HOPS complexes

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of VPS16 mRNA

NCBI chr 3:117,622,534...117,644,041
Ensembl chr 3:117,622,542...117,646,441

G

VPS39 subunit of HOPS complex

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of VPS39 mRNA

NCBI chr 3:107,266,846...107,304,884
Ensembl chr 3:107,267,310...107,304,975

G

VRK serine/threonine kinase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of VRK2 mRNA

NCBI chr14:100,313,771...100,434,520
Ensembl chr14:100,313,601...100,434,527

G

V-set immunoregulatory receptor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of VSIR mRNA

NCBI chr20:28,281,582...28,307,262
Ensembl chr20:28,281,596...28,303,878

G

WASP like actin nucleation promoting factor

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of WASL mRNA

NCBI chr 4:53,083,536...53,132,061
Ensembl chr 4:53,083,536...53,132,022

G

WEE1 G2 checkpoint kinase

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of WEE1 mRNA

NCBI chr 1:164,173,681...164,197,688
Ensembl chr 1:164,174,779...164,197,688

G

WAP four-disulfide core domain 12

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of WFDC12 mRNA

NCBI chr 3:152,861,461...152,862,784
Ensembl chr 3:152,862,341...152,862,690

G

WNK lysine deficient protein kinase 4

increases expression

chrysene results in increased expression of WNK4 mRNA

NCBI chr10:86,202,552...86,219,655
Ensembl chr10:86,188,812...86,231,829

G

WSC domain containing 2

increases expression

chrysene results in increased expression of WSCD2 mRNA

NCBI chr12:43,046,547...43,141,115
Ensembl chr12:43,048,043...43,088,591

G

WT1 transcription factor

increases expression

chrysene results in increased expression of WT1 mRNA

NCBI chr 3:91,566,540...91,613,653
Ensembl chr 3:91,567,001...91,613,643

G

X-box binding protein 1

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of XBP1 mRNA

NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693

G

X-prolyl aminopeptidase 2

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of XPNPEP2 mRNA

NCBI chr X:127,287,765...127,317,036
Ensembl chr X:127,287,979...127,317,223

G

Yes1 associated transcriptional regulator

increases expression

chrysene results in increased expression of YAP1 mRNA

NCBI chr 8:5,095,705...5,166,808
Ensembl chr 8:5,095,722...5,167,010

G

Y box binding protein 1

increases expression

chrysene results in increased expression of YBX1 mRNA

NCBI chr 5:132,882,137...132,898,885
Ensembl chr 5:132,882,145...132,898,862

G

yippee-like 5

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of YPEL5 mRNA

NCBI chr 6:22,656,284...22,671,741
Ensembl chr 6:22,656,285...22,671,691

G

YTH N6-methyladenosine RNA binding protein C1

increases expression

chrysene results in increased expression of YTHDC1 mRNA

NCBI chr14:21,185,438...21,215,934
Ensembl chr14:21,185,440...21,216,028

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of YWHAZ mRNA

NCBI chr 7:67,941,353...67,963,651
Ensembl chr 7:67,940,017...67,963,668

G

zinc finger CCCH type containing 7 A

increases expression

chrysene results in increased expression of ZC3H7A mRNA

NCBI chr10:4,473,177...4,512,668
Ensembl chr10:4,473,203...4,512,665

G

zinc finger CCHC-type containing 7

increases expression

chrysene results in increased expression of ZCCHC7 mRNA

NCBI chr 5:58,992,558...59,173,308
Ensembl chr 5:58,993,290...59,173,300

G

zinc finger DHHC-type palmitoyltransferase 22

decreases expression

chrysene results in decreased expression of ZDHHC22 mRNA

NCBI chr 6:106,629,090...106,646,996
Ensembl chr 6:106,631,609...106,638,872

G

zinc finger protein 185

increases expression

chrysene results in increased expression of ZFP185 mRNA

NCBI chr X:150,831,869...150,877,652
Ensembl chr X:150,831,862...150,874,810

G

zinc finger protein 280D

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ZFP280D mRNA

NCBI chr 8:72,992,655...73,080,482
Ensembl chr 8:72,992,650...73,080,480

G

zinc finger protein 346

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ZFP346 mRNA

NCBI chr17:9,493,787...9,523,681
Ensembl chr17:9,493,803...9,523,635

G

zinc finger protein 365

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ZFP365 mRNA

NCBI chr20:20,666,240...20,689,734
Ensembl chr20:20,666,240...20,691,238

G

zinc finger protein 367

decreases expression
multiple interactions

chrysene results in decreased expression of ZFP367 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ZFP367 mRNA

PMID:26377693 PMID:27858113

NCBI chr17:965,161...984,290
Ensembl chr17:965,161...984,287

G

zinc finger protein 423

increases expression

chrysene results in increased expression of ZFP423 mRNA

NCBI chr19:19,111,213...19,407,373
Ensembl chr19:19,110,238...19,407,373

G

zinc finger protein 62

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ZFP62 mRNA

NCBI chr10:33,522,618...33,539,446
Ensembl chr10:33,500,323...33,542,013

G

zinc finger protein 628

decreases expression
multiple interactions

chrysene results in decreased expression of ZFP628 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ZFP628 mRNA

PMID:26377693 PMID:27858113

NCBI chr 1:68,913,600...68,921,186
Ensembl chr 1:68,910,401...68,921,243

G

zinc finger protein 664

decreases expression

chrysene results in decreased expression of ZFP664 mRNA

NCBI chr12:31,767,792...31,796,038
Ensembl chr12:31,767,720...31,796,545

G

zinc finger protein 710

increases expression

chrysene results in increased expression of ZFP710 mRNA

NCBI chr 1:133,966,256...134,036,593
Ensembl chr 1:134,024,267...134,036,601

G

zinc finger, matrin type 3

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of ZMAT3 mRNA

NCBI chr 2:115,106,046...115,136,888
Ensembl chr 2:115,106,966...115,136,863

G

zinc finger, MYND-type containing 15

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ZMYND15 mRNA

NCBI chr10:55,171,198...55,177,812
Ensembl chr10:55,171,198...55,177,812

G

zinc finger, MYND-type containing 8

multiple interactions

[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ZMYND8 mRNA

NCBI chr 3:154,528,917...154,629,532
Ensembl chr 3:154,529,043...154,628,463

chrysen-6-ol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

progesterone receptor

multiple interactions

6-hydroxychrysene inhibits the reaction [Progesterone binds to PGR protein]; [Progesterone co-treated with 6-hydroxychrysene] results in decreased expression of PGR mRNA

NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344

G

UDP glucuronosyltransferase family 1 member A1

increases glucuronidation
multiple interactions

UGT1A1 protein results in increased glucuronidation of 6-hydroxychrysene
[Methylcholanthrene results in increased expression of UGT1A1 protein] which results in increased glucuronidation of 6-hydroxychrysene

NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase family 1 member A6

increases glucuronidation

UGT1A6 protein results in increased glucuronidation of 6-hydroxychrysene

NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	19808
role	19784
biological role	19782
aetiopathogenetic role	19166
carcinogenic agent	18496
polycyclic arene	17023
ortho-fused polycyclic arene	9806
chrysene	870
hydroxychrysene +	3
Path 2
Term	Annotations
CHEBI ontology	19808
subatomic particle	19806
composite particle	19806
hadron	19806
baryon	19806
nucleon	19806
atomic nucleus	19806
atom	19806
main group element atom	19756
main group molecular entity	19756
s-block molecular entity	19595
hydrogen molecular entity	19582
hydrides	19095
organic hydride	18669
organic fundamental parent	18669
hydrocarbon	18415
cyclic hydrocarbon	17215
arene	17195
polycyclic arene	17023
ortho-fused polycyclic arene	9806
chrysene	870
hydroxychrysene +	3

paths to the root